{"content":"<li class=\"n-box-item date-title\" data-end=\"1511240399\" data-start=\"1511154000\" data-txt=\"Monday, December 23, 2019\">Monday, November 20, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3313689\" data-ts=\"1511220683\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313689-starboard-value-discloses-10_7-stake-in-mellanox-wants-to-explore-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Starboard Value discloses 10.7% stake in Mellanox, wants to explore sale</a></h4><ul>     <li>Mellanox Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) <font color='green'>+5.8%</font> after-hours as Starboard Value <a href=\"http://archive.fast-edgar.com//20171120/AF22D622U2224ZZ222282ZDMNSFSL222V292/\" target=\"_blank\">discloses taking a 10.7% stake</a> in the company and urges MLNX to improve its margins and <a href=\"https://www.wsj.com/articles/starboard-value-takes-10-7-stake-in-mellanox-technologies-1511216509\" target=\"_blank\">explore a potential sale</a>.</li>     <li>Starboard says MLNX is spending too much on R&amp;D and other corporate expenses to sufficiently grow revenue, sacrificing margins compared with peers, and wants the company to improve its operations and potentially explore a deal to boost the stock.</li>     <li>Marvell Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group, Ltd.'>MRVL</a>) recently approached MLNX about a potential deal but was rebuffed, Starboard says, a response that convinced the activist investor that MLNX was hostile to potential deals, <em>WSJ</em> reports.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313689\" data-linked=\"Starboard Value discloses 10.7% stake in Mellanox, wants to explore sale\" data-tweet=\"$MLNX $MLNX $MRVL - Starboard Value discloses 10.7% stake in Mellanox, wants to explore sale https://seekingalpha.com/news/3313689-starboard-value-discloses-10_7-stake-in-mellanox-wants-to-explore-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3313689-starboard-value-discloses-10_7-stake-in-mellanox-wants-to-explore-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313688\" data-ts=\"1511219418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNCR\" target=\"_blank\">SNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313688-synchronoss-techminus-4-after-receiving-nasdaq-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchronoss Tech -4% after receiving Nasdaq warning</a></h4><ul>     <li>Synchronoss Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) <font color='red'>-3.9%</font> after-hours as it reports receiving an anticipated letter from Nasdaq saying its stock is <a href=\"https://seekingalpha.com/pr/17007827-synchronoss-technologies-receives-anticipated-nasdaq-letter-intends-request-hearing\" target=\"_blank\">subect to suspension and delisting procedures</a> unless it  requests a hearing before a Nasdaq panel by Nov. 22, which the company says it will do.</li>     <li>SNCR says it will present its plan to regain compliance at the hearing and request the continued listing of its shares on Nasdaq while it works to become current in its periodic public       filings with the SEC.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313688\" data-linked=\"Synchronoss Tech -4% after receiving Nasdaq warning\" data-tweet=\"$SNCR - Synchronoss Tech -4% after receiving Nasdaq warning https://seekingalpha.com/news/3313688-synchronoss-techminus-4-after-receiving-nasdaq-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3313688-synchronoss-techminus-4-after-receiving-nasdaq-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313681\" data-ts=\"1511217359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313681-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/ASYS' title='Amtech Systems, Inc.'>ASYS</a> <font color='green'>+13.3%</font>. <a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a> <font color='green'>+5.9%</font>. <a href='https://seekingalpha.com/symbol/CRR' title='CARBO Ceramics Inc.'>CRR</a> <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx'>ARDX</a> <font color='green'>+3.6%</font>. <a href='https://seekingalpha.com/symbol/VCO-OLD' title='Vina Concha y Toro S.A. &#40;ADR&#41;'>VCO-OLD</a> <font color='green'>+3.6%</font>.</li>     <li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/ZTO' title='ZTO Express'>ZTO</a> <font color='red'>-11.1%</font>. <a href='https://seekingalpha.com/symbol/DS' title='Drive Shack Inc'>DS</a> <font color='red'>-10.1%</font>. <a href='https://seekingalpha.com/symbol/SN' title='Sanchez Energy Corporation'>SN</a> <font color='red'>-10.1%</font>. <a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies Inc.'>A</a>&nbsp;<font color='red'>-4.9</font><font color='red'>%</font>. <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>&nbsp;<font color='red'>-3.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313681\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ASYS $PANW $CRR - After Hours Gainers / Losers https://seekingalpha.com/news/3313681-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3313681-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313680\" data-ts=\"1511216926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIPS\" target=\"_blank\">VIPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313680-vipshop-holdings-up-in-late-trade-after-q3-revenue-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vipshop Holdings up in late trade after Q3 revenue beat</a></h4><ul>   <li>Vipshop Holdings (NYSE:<a href='https://seekingalpha.com/symbol/VIPS' title='Vipshop Holdings'>VIPS</a>) is <font color='green'>up 1.6%</font> after hours, recouping some of today's losses, after posting <a href=\"https://seekingalpha.com/news/3313613-vipshop-holdings-eps-line-beats-revenue\" target=\"_blank\">Q3 earnings</a> where revenues showed solid growth and beat analyst expectations.</li><li>Revenues grew more than 27% to 15.3B yuan (about $2.3B). Gross profit rose 19.4% to 3.5B yuan (about $526M).</li>    <li>Net income (non-GAAP), meanwhile, dipped slightly to 559.8M yuan (about $84.1M) vs. a year-ago 595.5M yuan.</li>    <li>Active customers (trailing 12 months) rose 22% to 60.5M; total orders were up 23% Y/Y to 74M.</li>    <li>For Q4, it's expecting total net revenue of 22.8B-23.8B yuan (   ), a growth rate of 20-25%.</li>    <li><a href=\"http://ir.vip.com/\" target=\"_blank\">Conference call</a> to come tomorrow at 8 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17007777-vipshop-reports-unaudited-third-quarter-2017-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3313680\" data-linked=\"Vipshop Holdings up in late trade after Q3 revenue beat\" data-tweet=\"$VIPS - Vipshop Holdings up in late trade after Q3 revenue beat https://seekingalpha.com/news/3313680-vipshop-holdings-up-in-late-trade-after-q3-revenue-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3313680-vipshop-holdings-up-in-late-trade-after-q3-revenue-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313659\" data-ts=\"1511215133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSN\" target=\"_blank\">CLSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313659-celsion-builds-on-up-move-ahead-of-thermodox-study-data-shares-ahead-20-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celsion builds on up move ahead of ThermoDox study data; shares ahead 20% after hours</a></h4><ul><li>Nano cap Celsion (NASDAQ:<a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a>) is up&nbsp;<font color='green'>20%</font>&nbsp;after hours on robust volume, adding to today's&nbsp;<font color='green'>8%&nbsp;</font>move on lighter-than-normal volume. Investors appear to be taking positions ahead a November 27 <a href=\"https://seekingalpha.com/pr/17007028-celsion-announces-publication-study-thermodox-ultrasound-tardox-study-protocol-journal\" target=\"_blank\">presentation </a>of results from a Phase 1 study, TARDOX, evaluating the feasibility of a ThermoDox/focused ultrasound combination to treat liver tumors. The data will be presented at RSNA in Chicago.</li><li>The primary endpoint of the study was the doxorubicin concentration in tumor biopsies before and after focused ultrasound-mediated hyperthermia as measured by high performance liquid chromatography.</li><li>ThermoDox is encapsulated doxorubicin. After infusion, it is heated to a specific temperature which releases the cancer drug directly into a tumor.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301176-celsion-8-percent-heat-study-publication-therapeutic-potential-thermodox-rfa\" target=\"_blank\">Celsion up 8% on HEAT study publication and therapeutic potential of ThermoDox + RFA</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313659\" data-linked=\"Celsion builds on up move ahead of ThermoDox study data; shares ahead 20% after hours\" data-tweet=\"$CLSN - Celsion builds on up move ahead of ThermoDox study data; shares ahead 20% after hours https://seekingalpha.com/news/3313659-celsion-builds-on-up-move-ahead-of-thermodox-study-data-shares-ahead-20-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3313659-celsion-builds-on-up-move-ahead-of-thermodox-study-data-shares-ahead-20-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313644\" data-ts=\"1511213892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313644-palo-alto-networksplus-6_7-after-q1-beats-upside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palo Alto Networks +6.7% after Q1 beats, upside guidance</a></h4><ul><li>        Palo Alto Networks (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a>) shares are&nbsp;<font color='green'>up 6.7%</font>&nbsp;aftermarket following a Q1 report that beat EPS and revenue estimates and featured upside guidance. Q2 guidance has revenue from $518M to $528M (consensus: $519.89M) and EPS from $0.78 to $0.80 (consensus: $0.77).</li><li>               FY18 guidance: revenue, $2.145B to $2.185B (consensus: $2.15B); EPs, $3.35 to $3.41 (consensus: $3.32).&nbsp;</li><li>               Financials: Cash from operating activities, $274.1M; FCF, $241.9M; operating expenses, $418.4M; cash and equivalents, $842.6M, current liabilities, $1.7B.&nbsp;</li><li>               Staff change: Palo Alto announces Kathy Bonanno as the new CFO. Bonanno has worked at Palo Alto since 2014 and previously worked at Symantec.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17007790-palo-alto-networks-reports-fiscal-first-quarter-2018-financial-results\" target=\"_blank\">Press release</a>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313620-palo-alto-networks-beats-0_05-beats-revenue\" target=\"_blank\">Palo Alto Networks beats by $0.05, beats on revenue</a> (Nov. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313644\" data-linked=\"Palo Alto Networks +6.7% after Q1 beats, upside guidance\" data-tweet=\"$PANW - Palo Alto Networks +6.7% after Q1 beats, upside guidance https://seekingalpha.com/news/3313644-palo-alto-networksplus-6_7-after-q1-beats-upside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3313644-palo-alto-networksplus-6_7-after-q1-beats-upside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313628\" data-ts=\"1511213715\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CO\" target=\"_blank\">CO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313628-china-cord-blood-fiscal-q2-top-line-up-27-earnings-up-307-cash-flow-ops-up-58\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Cord Blood fiscal Q2 top line up 27%; earnings up 307%; cash flow ops up 58%</a></h4><ul><li>China Cord Blood (NYSE:<a href='https://seekingalpha.com/symbol/CO' title='Global Cord Blood Corporation'>CO</a>) <a href=\"https://seekingalpha.com/pr/17007805-china-cord-blood-corporation-reports-financial-results-second-quarter-first-half-fiscal-2018\" target=\"_blank\">fiscal Q2 results</a> (RMB millions): Revenues: 234.6 (+27.4%).</li><li>Net Income: 67.6 (+307.2%); EPS: 0.60 (+172.7%); CF Ops: 215.3 (+58.0%).</li><li>Subscriber base as of 9/30: 620.7K.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313628\" data-linked=\"China Cord Blood fiscal Q2 top line up 27%; earnings up 307%; cash flow ops up 58%\" data-tweet=\"$CO - China Cord Blood fiscal Q2 top line up 27%; earnings up 307%; cash flow ops up 58% https://seekingalpha.com/news/3313628-china-cord-blood-fiscal-q2-top-line-up-27-earnings-up-307-cash-flow-ops-up-58?source=tweet\" data-url=\"https://seekingalpha.com/news/3313628-china-cord-blood-fiscal-q2-top-line-up-27-earnings-up-307-cash-flow-ops-up-58\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313626\" data-ts=\"1511212849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTU\" target=\"_blank\">INTU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313626-intuit-reports-q1-beats-in-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intuit reports Q1 beats, in-line guidance</a></h4><ul><li>        Intuit (NASDAQ:<a href='https://seekingalpha.com/symbol/INTU' title='Intuit Inc.'>INTU</a>) shares are&nbsp;<font color='red'>down nearly 1%</font>&nbsp;aftermarket despite Q1 results that beat EPS and revenue estimates. Q2 guidance has revenue from $1.16B to $1.18B (consensus: $1.12B) and EPS from $0.31 to $0.34 (consensus: $0.32).</li><li>               FY18 guidance: revenue, $5.64B to $5.74B (consensus: $5.69B); EPS, $4.90 to $5.00 (consensus: $4.95).&nbsp;</li><li>               Segment revenue growth: Small Business &amp; Self-Employed Group, +17%; Consumer and Strategic Partner Groups, +7%.&nbsp;</li><li>               Key metrics: QuickBooks Online subscribers, 2.55M (+56%); QuickBooks Online Self-Employed, 425K.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17007745-intuit-first-quarter-revenue-increased-14-percent-led-quickbooks-online-subscriber-growth-56\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313607-intuit-beats-0_06-beats-revenue\" target=\"_blank\">Intuit beats by $0.06, beats on revenue</a> (Nov. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313626\" data-linked=\"Intuit reports Q1 beats, in-line guidance\" data-tweet=\"$INTU - Intuit reports Q1 beats, in-line guidance https://seekingalpha.com/news/3313626-intuit-reports-q1-beats-in-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3313626-intuit-reports-q1-beats-in-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313625\" data-ts=\"1511212775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/A\" target=\"_blank\">A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313625-agilent-fiscal-q4-top-line-up-7-earnings-up-41-cash-flow-ops-up-23-soft-q1-guidance-sinks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agilent fiscal Q4 top line up 7%; earnings up 41%; cash flow ops up 23%; soft Q1 guidance sinks shares, down 5% after hours</a></h4><ul><li>Agilent (NYSE:<a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies Inc.'>A</a>) <a href=\"https://seekingalpha.com/pr/17007774-agilent-technologies-reports-fourth-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">fiscal Q4 results</a> ($M): Revenues: 1,189 (+7.0%); Life Sciences: 575 (+4.9%); Diagnostics and Genomics: 210 (+8.8%); CrossLab: 404 (+9.2%).</li><li>Net Income: 177 (+40.6%); Non-GAAP Net Income: 218 (+13.0%);&nbsp;EPS: 0.54 (+42.1%); Non-GAAP EPS: 0.67 (+13.6%); CF Ops: 288 (+23.1%).</li><li><strong>Fiscal 2018 Guidance</strong>: Revenues: $4.72B - 4.74B; Non-GAAP EPS: $2.50 - 2.56.</li><li><strong>Fiscal Q1 Guidance</strong>: Revenues: $1.145B - 1.165B; Non-GAAP EPS: $0.55 - 0.57.</li><li>Fiscal Q1 consensus is EPS of $0.60 on revenues of $1.15B.</li><li>Shares are down&nbsp;<font color='red'>5%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313625\" data-linked=\"Agilent fiscal Q4 top line up 7%; earnings up 41%; cash flow ops up 23%; soft Q1 guidance sinks shares, down 5% after hours\" data-tweet=\"$A - Agilent fiscal Q4 top line up 7%; earnings up 41%; cash flow ops up 23%; soft Q1 guidance sinks shares, down 5% after hours https://seekingalpha.com/news/3313625-agilent-fiscal-q4-top-line-up-7-earnings-up-41-cash-flow-ops-up-23-soft-q1-guidance-sinks?source=tweet\" data-url=\"https://seekingalpha.com/news/3313625-agilent-fiscal-q4-top-line-up-7-earnings-up-41-cash-flow-ops-up-23-soft-q1-guidance-sinks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313623\" data-ts=\"1511212643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313623-urban-outfitters-rallies-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urban Outfitters rallies after earnings</a></h4><ul><li>Urban Outfitters (NASDAQ:<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a>) tops revenue estimates with its <a href=\"https://seekingalpha.com/pr/17007778-urbn-reports-record-q3-sales\" target=\"_blank\">Q3 </a>report after knocking out a 1% increase in comparable sales in the retail segment.</li><li>Wholesale segment sales increased 8.7% during the quarter.</li><li>Gross margin came in at 34.1% of sales, level with the expectation of analysts.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313615-urban-outfitters-beats-0_08-beats-revenue\" target=\"_blank\">Urban Outfitters beats by $0.08, beats on revenue</a> (Nov. 20)</li><li>URBN&nbsp;<font color='green'>+6.12%</font>&nbsp;AH to $30.00.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313623\" data-linked=\"Urban Outfitters rallies after earnings\" data-tweet=\"$URBN - Urban Outfitters rallies after earnings https://seekingalpha.com/news/3313623-urban-outfitters-rallies-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3313623-urban-outfitters-rallies-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313622\" data-ts=\"1511212374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASYS\" target=\"_blank\">ASYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313622-amtech-beats-0_42-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amtech beats by $0.42, beats on revenue</a></h4><ul><li>Amtech (NASDAQ:<a href='https://seekingalpha.com/symbol/ASYS' title='Amtech Systems, Inc.'>ASYS</a>): Q4 EPS of $0.51 <font color='green'>beats by $0.42</font>.</li><li>Revenue of $54.7M (+29.0% Y/Y) <font color='green'>beats by $7.8M</font>.</li><li>Shares <font color='green'>+8.6%</font>.</li><li><a href='https://seekingalpha.com/pr/17007789-amtech-reports-fourth-quarter-fiscal-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3313622\" data-linked=\"Amtech beats by $0.42, beats on revenue\" data-tweet=\"$ASYS - Amtech beats by $0.42, beats on revenue https://seekingalpha.com/news/3313622-amtech-beats-0_42-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3313622-amtech-beats-0_42-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313605\" data-ts=\"1511211397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAIN\" target=\"_blank\">HAIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313605-hain-celestial-jumps-on-talk-of-nestle-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hain Celestial jumps on talk of Nestle interest</a></h4><ul><li>Hain Celestial (<a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a> <font color='green'>+2.5%</font>) jumps after Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2017-11-20/nestle-is-among-potential-suitors-for-hain-celestial\" target=\"_blank\">reports</a> that Nestle (<a href='https://seekingalpha.com/symbol/NSRGY' title='Nestle S.A. ADR'>OTCPK:NSRGY</a>) is interested in making a bid for the food company.</li><li>Preliminary talks between Nestle and Hain about a full or partial sale have already taken place.</li><li>Hain has been the subject of several speculative M&amp;A stories in the past.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313605\" data-linked=\"Hain Celestial jumps on talk of Nestle interest\" data-tweet=\"$HAIN $HAIN $NSRGY - Hain Celestial jumps on talk of Nestle interest https://seekingalpha.com/news/3313605-hain-celestial-jumps-on-talk-of-nestle-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3313605-hain-celestial-jumps-on-talk-of-nestle-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313603\" data-ts=\"1511210977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313603-moodys-notes-mounting-challenges-for-ge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moody&#39;s notes &#39;mounting challenges&#39; for GE</a></h4><ul><li>Coming on the heels of last week's credit rating downgrade of General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-1.3%</font>), Moody's says <a href=\"https://www.marketwatch.com/story/ges-stock-falls-after-moodys-says-mounting-challenges-outweight-dividend-cut-benefit-2017-11-20\" target=\"_blank\">any cash flow benefit</a> from the halving of the dividend will be outweighed by \"mounting end-market challenges.\"</li><li>The agency expects \"severe deterioration\" in GE's power business at least through the end of 2019, continued weakness in oil and gas, and struggles in transportation.</li><li><a href=\"https://www.moodys.com/MdcAccessDeniedCh.aspx?lang=en&amp;cy=global&amp;Source=https%3a%2f%2fwww.moodys.com%2fviewresearchdoc.aspx%3fdocid%3dPBC_1101193%26lang%3den%26cy%3dglobal\" target=\"_blank\">Full report</a> (subscription required)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313603\" data-linked=\"Moody&#39;s notes &#39;mounting challenges&#39; for GE\" data-tweet=\"$GE - Moody&#39;s notes &#39;mounting challenges&#39; for GE https://seekingalpha.com/news/3313603-moodys-notes-mounting-challenges-for-ge?source=tweet\" data-url=\"https://seekingalpha.com/news/3313603-moodys-notes-mounting-challenges-for-ge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313602\" data-ts=\"1511210375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DY\" target=\"_blank\">DY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313602-dycomplus-9-on-stronger-expected-quarter-outlook-for-new-projects\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dycom +9% on stronger than expected quarter, outlook for new projects</a></h4><ul>     <li>Dycom Industries (<a href='https://seekingalpha.com/symbol/DY' title='Dycom Industries Inc.'>DY</a> <font color='green'>+8.7%</font>) surges higher after reporting better than expected <a href=\"https://seekingalpha.com/news/3313400-dycom-industries-beats-0_09-beats-revenue\" target=\"_blank\">FQ1 earnings</a> and weak guidance for the January quarter, but it says 1 GB connections are in demand; DY issued its report a day earlier than planned because it says certain documents were subject to unauthorized access after the market closed on Friday.</li>     <li>DY says it expects total contract revenues for the current quarter of $645M-$675M, down from $756M for FQ1 largely because of a short-term moderation by one of its larger customers; quarterly revenues thereafter should range from <a href=\"https://seekingalpha.com/article/4126450-dycom-industries-inc-2018-q1-results-earnings-call-slides\" target=\"_blank\">in-line to a low single digit increase</a> as a percentage of revenue compared to the year-ago quarter.</li><li>DY says fiber deployments in contemplation of newly emerging wireless technologies have begun in many parts of the U.S., and expects a \"significant number\" of new project initiations to occur \"in the near term.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313602\" data-linked=\"Dycom +9% on stronger than expected quarter, outlook for new projects\" data-tweet=\"$DY - Dycom +9% on stronger than expected quarter, outlook for new projects https://seekingalpha.com/news/3313602-dycomplus-9-on-stronger-expected-quarter-outlook-for-new-projects?source=tweet\" data-url=\"https://seekingalpha.com/news/3313602-dycomplus-9-on-stronger-expected-quarter-outlook-for-new-projects\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313600\" data-ts=\"1511209132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWX\" target=\"_blank\">TWX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313600-time-warnerminus-1-doj-said-ready-to-announce-merger-lawsuit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Time Warner -1%; DOJ said ready to announce merger lawsuit</a></h4><ul>     <li>Time Warner (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>) shares are taking a sudden dip, <font color='red'>down 1%</font>, on word that an impending antitrust announcement involves news of a Justice Dept. lawsuit to stop a takeover by AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color='green'>+0.8%</font>).</li>     <li>The DOJ&nbsp;will brief the media this afternoon on some antitrust news; a person familiar with the announcement tells Bloomberg it's about the $85B T-TWX deal.</li>   <li><b>Updated 3:31 p.m.:</b> Time Warner's now <font color='red'>down 1.4%</font> (AT&amp;T shed top gains but is <font color='green'>up 0.4%</font>) and other media stocks are feeling at least a mild headwind: <a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a> <font color='red'>-0.7%</font>; <a href='https://seekingalpha.com/symbol/CBS' title='CBS Corporation'>CBS</a> <font color='red'>-1.4%</font>; <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='red'>-2%</font>; <a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> <font color='red'>-1.1%</font>; <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='red'>-0.2%</font>.</li><li><strong>Updated 4:18 p.m.:</strong> Executives from AT&amp;T&nbsp;and Time Warner will hold a <a href=\"https://seekingalpha.com/pr/17007817-t-time-warner-hold-press-conference-5-30pm-est-november-20\" target=\"_blank\">press conference</a> at 5:30 p.m.; AT&amp;T chief Randall Stephenson will speak. (<a href=\"https://edge.media-server.com/m6/p/sahegutr\" target=\"_blank\">view here</a>)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313600\" data-linked=\"Time Warner -1%; DOJ said ready to announce merger lawsuit\" data-tweet=\"$TWX $TWX $DIS - Time Warner -1%; DOJ said ready to announce merger lawsuit https://seekingalpha.com/news/3313600-time-warnerminus-1-doj-said-ready-to-announce-merger-lawsuit?source=tweet\" data-url=\"https://seekingalpha.com/news/3313600-time-warnerminus-1-doj-said-ready-to-announce-merger-lawsuit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>88&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313598\" data-ts=\"1511208472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLMN\" target=\"_blank\">BLMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313598-bloomin-brands-spikes-after-jana-partners-applies-pressure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomin&#39; Brands spikes after Jana Partners applies pressure</a></h4><ul> <li>Bloomin' Brands (<a href='https://seekingalpha.com/symbol/BLMN' title='Bloomin&#39; Brands'>BLMN</a> <font color='green'>+11.5%</font>) spikes after Jana Partners discloses that it holds a 8.74% stake in the company and will push for a review of strategic options, including a potential sale.</li> <li><a href=\"https://seekingalpha.com/filing/3772815\" target=\"_blank\">SEC Form 13D </a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3313598\" data-linked=\"Bloomin&#39; Brands spikes after Jana Partners applies pressure\" data-tweet=\"$BLMN - Bloomin&#39; Brands spikes after Jana Partners applies pressure https://seekingalpha.com/news/3313598-bloomin-brands-spikes-after-jana-partners-applies-pressure?source=tweet\" data-url=\"https://seekingalpha.com/news/3313598-bloomin-brands-spikes-after-jana-partners-applies-pressure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313596\" data-ts=\"1511208101\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PENN\" target=\"_blank\">PENN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313596-penn-national-gaming-continues-to-track-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Penn National Gaming continues to track higher</a></h4><ul> <li>Barclays lifts its price target on Penn National Gaming (<a href='https://seekingalpha.com/symbol/PENN' title='Penn National Gaming, Inc.'>PENN</a> <font color='green'>+1.8%</font>) to <a href=\"https://twitter.com/RatingsNetwork/status/932659182117031936\" target=\"_blank\">$30</a> amid continuing enthusiasm over the casino company's prospects.</li> <li>The investment firm moves its valuation on the stock higher due to Penn's improved margins profile and the undercurrent of M&amp;A potential in the sector.</li> <li>Shares of Penn National Gaming have doubled this year and struck a new multi-year high of $28.02 earlier today.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3313596\" data-linked=\"Penn National Gaming continues to track higher\" data-tweet=\"$PENN - Penn National Gaming continues to track higher https://seekingalpha.com/news/3313596-penn-national-gaming-continues-to-track-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3313596-penn-national-gaming-continues-to-track-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313592\" data-ts=\"1511207702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313592-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TSRI' title='TSR, Inc.'>TSRI</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Inc.'>ATOM</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CPSH' title='CPS Technologies Corp.'>CPSH</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SSTI' title='ShotSpotter'>SSTI</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313592\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$TSRI $XNET $MARK - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3313592-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3313592-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313589\" data-ts=\"1511207137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTW\" target=\"_blank\">MTW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313589-manitowoc-upped-to-buy-seaport-reverse-split-takes-effect\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Manitowoc upped to Buy at Seaport as reverse split takes effect</a></h4><ul>     <li>Manitowoc (<a href='https://seekingalpha.com/symbol/MTW' title='Manitowoc Company, Inc.'>MTW</a> <font color='green'>+2.6%</font>) is <a href=\"https://www.streetinsider.com/Analyst+Comments/Seaport+Global+Securities+Upgrades+Manitowoc+%28MTW%29+to+Buy/13525657.html\" target=\"_blank\">upgraded to Buy</a> from Neutral at Seaport Global with a new $48 price target is $48 from a reverse-split adjusted $38, as the company's 1-for-4 reverse split takes effect today.</li>     <li>In the past, MTW's strong execution on the turnaround was more than offset by further downside in the crane cycle, but this time around, Seaport says the company detected more confidence that end markets are in a bottoming phase, and that new products such as the TMS9000-2 which were not available last year are gaining traction.</li><li>Seaport also notes MTW's towers are booked well through H1 2018 and competitor comments on boom truck demand remain very positive.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313589\" data-linked=\"Manitowoc upped to Buy at Seaport as reverse split takes effect\" data-tweet=\"$MTW - Manitowoc upped to Buy at Seaport as reverse split takes effect https://seekingalpha.com/news/3313589-manitowoc-upped-to-buy-seaport-reverse-split-takes-effect?source=tweet\" data-url=\"https://seekingalpha.com/news/3313589-manitowoc-upped-to-buy-seaport-reverse-split-takes-effect\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313588\" data-ts=\"1511207028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313588-ziopharm-gives-up-early-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ziopharm gives up early gains</a></h4><ul><li>\"Virus in the head still gives up headaches,\" writes Guggenheim's Tony Butler. A Phase 3 trial, he says, will be necessary to clarify the benefit of&nbsp;Ad-RTS-IL-12 + veledimex.</li><li>Source: Bloomberg</li><li><a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a> is reversing sharp early gains, now&nbsp;<font color='red'>down 3.8%</font>&nbsp;on the session.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313429-ziopharms-gene-therapy-candidate-ad-rts-hilminus-12-shows-positive-effect-treatment-resistant\" target=\"_blank\">ZIOPHARM's gene therapy candidate Ad-RTS-hIL-12 shows positive effect in treatment-resistant brain cancer in early-stage study; shares ahead 13% premarket</a> (Nov. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313588\" data-linked=\"Ziopharm gives up early gains\" data-tweet=\"$ZIOP - Ziopharm gives up early gains https://seekingalpha.com/news/3313588-ziopharm-gives-up-early-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3313588-ziopharm-gives-up-early-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313584\" data-ts=\"1511205952\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHU\" target=\"_blank\">CHU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313584-philippines-courts-chinese-entry-domestic-telecom-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Philippines courts Chinese entry into domestic telecom market</a></h4><ul>   <li>Philippine President Rodrigue Duterte says he's offering China a chance to <a href=\"https://finance.yahoo.com/m/0016b73c-f48d-3a4a-8b56-5619e09ea7a8/ss_philippines%26%2339%3B-duterte.html\" target=\"_blank\">come in and compete</a> against what he calls a telecom duopoly.</li>    <li>It's not clear, though, whether China's state-owned telecoms would take him up on it, including dominant player China Mobile (<a href=\"http://seekingalpha.com/symbol/CHL\" target=\"_blank\">CHL</a> <font color='green'>+0.3%</font>), China Telecom (<a href=\"http://seekingalpha.com/symbol/CHA\" target=\"_blank\">CHA</a> <font color='red'>-1%</font>) or China Unicom (NYSE:<a href='https://seekingalpha.com/symbol/CHU' title='China Unicom &#40;Hong Kong&#41; Limited'>CHU</a>) -- all of which have been slow to expand beyond a sheltered home market.</li>    <li>The Philippine market is dominated by Globe Telecom (<a href=\"http://seekingalpha.com/symbol/GTMEY\" target=\"_blank\">GTMEY</a> <font color='red'>-1.1%</font>) and PLDT (<a href=\"http://seekingalpha.com/symbol/PHI\" target=\"_blank\">PHI</a> <font color='red'>-2.3%</font>).</li>    <li>An attempted entry by China's ZTE (<a href='https://seekingalpha.com/symbol/ZTCOY' title='Zte Corp. ADR'>OTCPK:ZTCOY</a>) to build a national broadband network in 2007 was scrapped after allegations of overpricing and kickbacks.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313584\" data-linked=\"Philippines courts Chinese entry into domestic telecom market\" data-tweet=\"$CHU $CHU $ZTCOY - Philippines courts Chinese entry into domestic telecom market https://seekingalpha.com/news/3313584-philippines-courts-chinese-entry-domestic-telecom-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3313584-philippines-courts-chinese-entry-domestic-telecom-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313580\" data-ts=\"1511204433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313580-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>    <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NTIC' title='Northern Technologies International Corporation'>NTIC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SNMX' title='Senomyx, Inc.'>SNMX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SDPI' title='Superior Drilling Products, Inc.'>SDPI</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GNE' title='Genie Energy Ltd.'>GNE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313580\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$NTIC $SNMX $SDPI - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3313580-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3313580-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313575\" data-ts=\"1511202433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LKM\" target=\"_blank\">LKM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313575-nq-mobile-gets-another-60m-in-divestment-payments-sharesplus-2_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NQ Mobile gets another $60M in divestment payments; shares +2.5%</a></h4><ul>   <li>In its latest update on payments tied to its divestment of FL Mobile and the Showself live social video business, NQ Mobile (<a href=\"http://seekingalpha.com/symbol/NQ\" target=\"_blank\">NQ</a> <font color='green'>+2.5%</font>) says it's <a href=\"https://seekingalpha.com/pr/17007143-nq-mobile-inc-provides-update-fl-mobile-divestment-sale-showselfs-live-social-video-business\" target=\"_blank\">gotten an additional 400M yuan</a> in payments.</li>    <li>That brings the total received from Tongfang Investment Fund Series SPC to 1.35B yuan of a previously agreed 3.32B yuan (about $500M). The entire sum was to come by the end of May, but Tongfang had said it needed more time.</li>    <li>Just over a week ago, Tongfang had made an additional payment of 800M yuan. It says it's still committed to completing the entire transaction.</li>    <li>Alongside the news, NQ says it negotiated with Zhongzhi Hi-Tech Overseas Investment Limited for <a href=\"https://seekingalpha.com/pr/17007136-nq-mobile-inc-provides-update-buyback-program\" target=\"_blank\">early partial redemption</a> of a convertible note, and will redeem $88M of a note issued to Zhongzhi in October 2016.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313575\" data-linked=\"NQ Mobile gets another $60M in divestment payments; shares +2.5%\" data-tweet=\"$LKM - NQ Mobile gets another $60M in divestment payments; shares +2.5% https://seekingalpha.com/news/3313575-nq-mobile-gets-another-60m-in-divestment-payments-sharesplus-2_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3313575-nq-mobile-gets-another-60m-in-divestment-payments-sharesplus-2_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313574\" data-ts=\"1511202379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AET\" target=\"_blank\">AET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313574-aetna-perks-up-1-on-report-cvs-takeover-imminent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aetna perks up 1% on report that CVS takeover imminent</a></h4><ul><li>Aetna (<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='green'>+1.2%</font>) is up 2.4% from its intraday low of $171 on a Dow Jones report that it could reach agreement to be <a href=\"https://twitter.com/usmansdesk/status/932674216943550464\" target=\"_blank\">acquired </a>by CVS Health (<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a> <font color='red'>-0.8%</font>) by the end of the month.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3308287-cvs-aetna-hope-seal-deal-soon-december-reuters\" target=\"_blank\">CVS/Aetna hope to seal deal as soon as December - Reuters</a> (Nov. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313574\" data-linked=\"Aetna perks up 1% on report that CVS takeover imminent\" data-tweet=\"$AET $AET $CVS - Aetna perks up 1% on report that CVS takeover imminent https://seekingalpha.com/news/3313574-aetna-perks-up-1-on-report-cvs-takeover-imminent?source=tweet\" data-url=\"https://seekingalpha.com/news/3313574-aetna-perks-up-1-on-report-cvs-takeover-imminent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313565\" data-ts=\"1511200175\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313565-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma, Inc.'>ACST</a> <font color='green'>+136%</font>. <a href='https://seekingalpha.com/symbol/OPHC' title='OptimumBank Holdings, Inc.'>OPHC</a> <font color='green'>+60%</font>. <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/TSRI' title='TSR, Inc.'>TSRI</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/NTIC' title='Northern Technologies International Corporation'>NTIC</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/IMI' title='Intermolecular, Inc.'>IMI</a> <font color='green'>+16%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MICT' title='Micronet Enertec Technologies, Inc.'>MICT</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/CREG' title='China Recycling Energy Corporation'>CREG</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/YECO-OLD' title='Yulong Eco-Materials'>YECO-OLD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/PRTA' title='Prothena Corp plc'>PRTA</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/GNE' title='Genie Energy Ltd.'>GNE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313565\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ACST $OPHC $DCIX - Midday Gainers / Losers https://seekingalpha.com/news/3313565-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3313565-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313559\" data-ts=\"1511198562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313559-bloomberg-gadfly-rio-tintos-interest-in-sqm-harbinger-of-lithium-weakness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg Gadfly: Rio Tinto&#39;s interest in SQM harbinger of lithium weakness</a></h4><ul>     <li>Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='green'>+0.2%</font>) is working with advisers on a bid for a stake in Sociedad Quimica &amp; Minera de Chile (<a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='red'>-6.1%</font>), according to Bloomberg, but Bloomberg's own David Fickling <a href=\"https://www.bloomberg.com/gadfly/articles/2017-11-20/rio-tinto-s-buying-again-expect-an-unhappy-ending-for-lithium\" target=\"_blank\">slams the idea</a>, saying Rio tends to buy into commodities right when prices are about to slump.</li>     <li>\"Over the years, Rio Tinto's major acquisitions have proved an eerily prescient contrarian indicator for commodities. When they buy,&nbsp;it's a good idea to sell,\" Fickling writes.</li>     <li>Bernstein analyst Paul Gait also fears Rio's interest is purely a move on the expectation of higher future lithium prices, and he thinks lithium is headed for oversupply and lithium carbonate prices will not climb much further, but hopes the company simply <a href=\"http://www.mining-journal.com/miningjournal/news/1309003/bernstein-hopes-rio-sqm\" target=\"_blank\">seeks access to SQM's data room</a>.</li>     <li>\"Information in such a process would presumably give detailed insight into SQM as a company and its place within the global lithium industry, and therefore would be particularly pertinent to Rio's own thinking around the Jadar project,\"&nbsp;Gait writes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313559\" data-linked=\"Bloomberg Gadfly: Rio Tinto&#39;s interest in SQM harbinger of lithium weakness\" data-tweet=\"$RIO $RIO $SQM - Bloomberg Gadfly: Rio Tinto&#39;s interest in SQM harbinger of lithium weakness https://seekingalpha.com/news/3313559-bloomberg-gadfly-rio-tintos-interest-in-sqm-harbinger-of-lithium-weakness?source=tweet\" data-url=\"https://seekingalpha.com/news/3313559-bloomberg-gadfly-rio-tintos-interest-in-sqm-harbinger-of-lithium-weakness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313557\" data-ts=\"1511198333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBSFY\" target=\"_blank\">PBSFY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313557-prosiebensat-1-higher-ceo-exit-fuels-acquisition-hopes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ProSiebenSat.1 higher as CEO exit fuels acquisition hopes</a></h4><ul>   <li>ProSiebenSat.1 (<a href='https://seekingalpha.com/symbol/PBSFY' title='ProSiebenSat.1 Media SE ADR'>OTCPK:PBSFY</a>) shares are <font color='green'>up 4.7%</font> in over-the-counter trading after an early exit from its CEO is <a href=\"https://www.reuters.com/article/us-prosieben-media/ma-hopes-boost-prosieben-after-ceo-quits-idUSKBN1DK13K?feedType=nl&amp;feedName=innovationNews&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=US%20Deals%20Today%202017-11-20&amp;utm_term=US%20Deals%20Today\" target=\"_blank\">restarting acquisition hopes</a> for shareholders.</li>    <li>Thomas Ebeling -- criticized for slamming the company's customer base following a number of poor outlooks for the commercial broadcaster -- will now leave in February, earlier than expected.</li>    <li>He had targeted a transition to digital for the broadcaster but investors mostly ended up confused this year, and the company's stock has been one of the DAX's worst performers.</li>    <li>One potential buyer is NBCUniversal (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='red'>-0.3%</font>), which previously indicated such an interest, though Comcast of late may be more interested in assets at Twenty-First Century Fox, and internationally focused Discovery Communications (<a href=\"http://seekingalpha.com/symbol/DISCA\" target=\"_blank\">DISCA</a> <font color='red'>-1.6%</font>) has its hands currently full with a Scripps Networks (<a href=\"http://seekingalpha.com/symbol/SNI\" target=\"_blank\">SNI</a> <font color='red'>-0.3%</font>) acquisition.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313557\" data-linked=\"ProSiebenSat.1 higher as CEO exit fuels acquisition hopes\" data-tweet=\"$PBSFY $PBSFY $CMCSA - ProSiebenSat.1 higher as CEO exit fuels acquisition hopes https://seekingalpha.com/news/3313557-prosiebensat-1-higher-ceo-exit-fuels-acquisition-hopes?source=tweet\" data-url=\"https://seekingalpha.com/news/3313557-prosiebensat-1-higher-ceo-exit-fuels-acquisition-hopes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313552\" data-ts=\"1511197289\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313552-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/RELV' title='Reliv&#39; International, Inc.'>RELV</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/LMNR' title='Limoneira'>LMNR</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313552\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SQBG $RELV $FIZZ - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3313552-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3313552-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313549\" data-ts=\"1511197047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313549-biocept-files-for-secondary-equity-offering-shares-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept files for secondary equity offering; shares down 9%</a></h4><ul><li>Biocept (<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='red'>-8.5%</font>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1044378/000095012317011047/bioc-s1_20171117.htm\" target=\"_blank\">preliminary prospectus</a> (S-1) for a public offering of stock and warrants. Prices, volumes and terms have yet to be finalized.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313549\" data-linked=\"Biocept files for secondary equity offering; shares down 9%\" data-tweet=\"$BIOC - Biocept files for secondary equity offering; shares down 9% https://seekingalpha.com/news/3313549-biocept-files-for-secondary-equity-offering-shares-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3313549-biocept-files-for-secondary-equity-offering-shares-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313547\" data-ts=\"1511196526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MXWL\" target=\"_blank\">MXWL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313547-roth-upgrades-maxwell-tech-ups-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roth upgrades Maxwell Tech, ups price target</a></h4><ul><li>        Roth Capital <a href=\"https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwjTsYW0zM3XAhWG5oMKHTzyACoQqQIIJygAMAA&amp;url=https%3A%2F%2Fwww.streetinsider.com%2FAnalyst%2BComments%2FRoth%2BCapital%2BUpgrades%2BMaxwell%2BTechnologies%2B%28MXWL%2B%29%2Bto%2BBuy%2BCiting%2BFavorable%2BRiskReward%2F13525698.html&amp;usg=AOvVaw11Y8ojPITxS0PXp47aGx-E\" target=\"_blank\">upgrades</a> Maxwell Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/MXWL' title='Maxwell Technologies, Inc.'>MXWL</a>) from Neutral to Buy and ups the price target by $2 to $7.</li><li>               Latest analyst recommendations (via <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=MXWL:NSQ\" target=\"_blank\">FT</a>): &nbsp;2 Outperform and 3 Hold.&nbsp;</li><li>               Median price target: $6.50.&nbsp;</li><li>               Maxwell shares are&nbsp;<font color='green'>up 5.7%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3312681-maxwell-technologies-ceo-acquires-230k-shares\" target=\"_blank\">Maxwell Technologies CEO acquires 230K shares</a> (Nov. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313547\" data-linked=\"Roth upgrades Maxwell Tech, ups price target\" data-tweet=\"$MXWL - Roth upgrades Maxwell Tech, ups price target https://seekingalpha.com/news/3313547-roth-upgrades-maxwell-tech-ups-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3313547-roth-upgrades-maxwell-tech-ups-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313546\" data-ts=\"1511196296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTSI\" target=\"_blank\">UTSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313546-utstarcom-to-five-year-high-after-product-sales-drive-profit-swing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UTStarcom to five-year high after product sales drive profit swing</a></h4><ul>   <li>UTStarcom Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/UTSI' title='UTStarcom, Inc.'>UTSI</a>) is <font color='green'>up 11.8%</font> on heavy volume and has hit a five-year high this morning after <a href=\"https://seekingalpha.com/news/3313398-utstarcom-reports-q3-results\" target=\"_blank\">Q3 earnings</a> where the company swung to a gain on revenues that grew nearly 60%.</li>    <li>Revenues of $26M surpassed one analyst estimate for $21M, with strength based on increased sales of 100G Packet Transport Network products.</li>    <li>Gross profit was $10.6M, making up 40.5% of net sales.</li>    <li>Net income, meanwhile, swung to a $2.2M gain vs. a loss of $1.8M a year ago.</li>    <li>Net sales breakout (non-GAAP): Equipment, $20.5M (up 98.3%); Services, $5.5M (down 8.4%).</li>    <li>Cash from operations was $1.9M; cash and equivalents as of Sept. 30 was $91.2M.</li>    <li><a href=\"https://seekingalpha.com/pr/17006824-utstarcom-reports-unaudited-financial-results-third-quarter-2017\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3313546\" data-linked=\"UTStarcom to five-year high after product sales drive profit swing\" data-tweet=\"$UTSI - UTStarcom to five-year high after product sales drive profit swing https://seekingalpha.com/news/3313546-utstarcom-to-five-year-high-after-product-sales-drive-profit-swing?source=tweet\" data-url=\"https://seekingalpha.com/news/3313546-utstarcom-to-five-year-high-after-product-sales-drive-profit-swing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313545\" data-ts=\"1511196288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIS\" target=\"_blank\">VIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313545-shah-capital-boosts-stake-in-vitamin-shoppe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shah Capital boosts stake in Vitamin Shoppe</a></h4><ul> <li>Shah Capital Management discloses that it holds a passive stake of 13.45% in Vitamin Shoppe (<a href='https://seekingalpha.com/symbol/VIS' title='Vanguard Industrials ETF'>VIS</a> <font color='green'>+0.5%</font>).</li> <li>The North Carolina-based investment firm reported a 5.45% position at the end Q3.</li> <li>Shares of Vitamin Shoppe are down 83% YTD.</li> <li><a href=\"https://seekingalpha.com/filing/3772539\" target=\"_blank\">SEC Form 13G</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3313545\" data-linked=\"Shah Capital boosts stake in Vitamin Shoppe\" data-tweet=\"$VIS - Shah Capital boosts stake in Vitamin Shoppe https://seekingalpha.com/news/3313545-shah-capital-boosts-stake-in-vitamin-shoppe?source=tweet\" data-url=\"https://seekingalpha.com/news/3313545-shah-capital-boosts-stake-in-vitamin-shoppe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313539\" data-ts=\"1511195095\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YNDX\" target=\"_blank\">YNDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313539-yandex-buys-foodfox-to-expand-uber-eats-rbc-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yandex buys Foodfox to expand Uber Eats, RBC says</a></h4><ul>   <li>Yandex (<a href=\"http://seekingalpha.com/symbol/YNDX\" target=\"_blank\">YNDX</a> <font color='green'>+1.8%</font>) has bought food-delivery service Foodfox for its Yandex.Taxi unit, RBC says, though Yandex calls the report \"speculation.\"</li>    <li>Such a deal would help the company expand Uber Eats in Russia, following the merger of that business with Yandex.Taxi in Russia and the Commonwealth of Independent States.</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313539\" data-linked=\"Yandex buys Foodfox to expand Uber Eats, RBC says\" data-tweet=\"$YNDX - Yandex buys Foodfox to expand Uber Eats, RBC says https://seekingalpha.com/news/3313539-yandex-buys-foodfox-to-expand-uber-eats-rbc-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3313539-yandex-buys-foodfox-to-expand-uber-eats-rbc-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313538\" data-ts=\"1511194767\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCPH\" target=\"_blank\">DCPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313538-deciphera-pharmas-lead-candidate-shows-positive-effect-in-early-stage-glioma-study-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deciphera Pharma&#39;s lead candidate shows positive effect in early-stage glioma study; shares ahead 6%</a></h4><ul><li>Thinly traded Deciphera Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a> <font color='green'>+6.4%</font>) perks up on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17006891-deciphera-pharmaceuticals-reports-data-ongoing-phase-1-clinical-study-dccminus-2618-22nd\" target=\"_blank\">announcement </a>of positive interim data from a Phase 1 clinical trial evaluating lead candidate DCC-2618 in patients with malignant gliomas, highly treatment-resistant cancers that occur in the brain and spinal cord. The results were presented at the Scientific Meeting and Education Day of the Society for Neuro-Oncology in San Francisco.</li><li>Off four evaluable patients with glioblastoma multiforme &#40;GBM&#41;, one experienced a partial response with 94% tumor reduction at week 84.</li><li>In the safety population (n=70), DCC-2618 was generally well-tolerated. Three dose-limiting toxicities were observed but were not considered clinically significant.</li><li><a href=\"https://www.deciphera.com/pipeline/dcc-2618/\" target=\"_blank\">DCC-2618</a> inhibits certain kinase enzymes (KIT and PDDGa) that play a key role in the proliferation and survival of certain cancers, including GBM, gastrointestinal stromal tumors and systemic mastocytosis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313538\" data-linked=\"Deciphera Pharma&#39;s lead candidate shows positive effect in early-stage glioma study; shares ahead 6%\" data-tweet=\"$DCPH - Deciphera Pharma&#39;s lead candidate shows positive effect in early-stage glioma study; shares ahead 6% https://seekingalpha.com/news/3313538-deciphera-pharmas-lead-candidate-shows-positive-effect-in-early-stage-glioma-study-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3313538-deciphera-pharmas-lead-candidate-shows-positive-effect-in-early-stage-glioma-study-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313509\" data-ts=\"1511193708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313509-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma, Inc.'>ACST</a> <font color='green'>+77%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/TCMD' title='Tactile Systems Technology'>TCMD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CELC' title='Celcuity, Inc.'>CELC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/AAC' title='AAC Holdings, Inc.'>AAC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SBPH' title='Spring Bank Pharmaceuticals'>SBPH</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BIVV' title='Bioverativ Inc.'>BIVV</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313509\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$ACST $EKSO $XOMA - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3313509-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3313509-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313534\" data-ts=\"1511193579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCS\" target=\"_blank\">BCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313534-two-notch-upgrade-for-barclays-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Two-notch upgrade for Barclays; shares up 2%</a></h4><ul><li>Things have sufficiently bottomed-out for Barclays (<a href='https://seekingalpha.com/symbol/BCS' title='Barclays PLC'>BCS</a> <font color='green'>+2.1%</font>) after shares underperformed the broad EU bank sector by 29% this year, says BAML, upgrading to Buy from Underperform.</li><li>The lender should be able to meet its 10% ROE target, with half of the plan coming from \"low hanging fruit,\" and the other half from \"plausible growth\" and a turnaround in the investment bank.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3313534\" data-linked=\"Two-notch upgrade for Barclays; shares up 2%\" data-tweet=\"$BCS - Two-notch upgrade for Barclays; shares up 2% https://seekingalpha.com/news/3313534-two-notch-upgrade-for-barclays-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3313534-two-notch-upgrade-for-barclays-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313533\" data-ts=\"1511193260\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTR\" target=\"_blank\">PTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313533-three-dead-due-to-apparent-gas-leak-petrochina-refinery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Three dead due to apparent gas leak at PetroChina refinery</a></h4><ul>     <li><a href=\"https://www.reuters.com/article/us-china-petrochina/three-dead-after-suspected-gas-leak-at-petrochina-refinery-media-idUSKBN1DK04S?il=0\" target=\"_blank\">Three workers were killed</a> and six others injured during a suspected gas leak at a refinery operated by PetroChina (<a href='https://seekingalpha.com/symbol/PTR' title='PetroChina Company Limited'>PTR</a> <font color='red'>-2.1%</font>) in Dalian over the weekend.</li>     <li>The men working for Henan Yanling Jingshun Petrochemical Machinery Equipment Co. were carrying out maintenance at the West Pacific Petrochemical plant in Liaoning province.</li>     <li>Production at the 200K bbl/day plant reportedly was not affected by the accident.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313533\" data-linked=\"Three dead due to apparent gas leak at PetroChina refinery\" data-tweet=\"$PTR - Three dead due to apparent gas leak at PetroChina refinery https://seekingalpha.com/news/3313533-three-dead-due-to-apparent-gas-leak-petrochina-refinery?source=tweet\" data-url=\"https://seekingalpha.com/news/3313533-three-dead-due-to-apparent-gas-leak-petrochina-refinery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313528\" data-ts=\"1511192725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHEK\" target=\"_blank\">CHEK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313528-check-cap-secures-2_5m-direct-capital-raise-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Check-Cap secures $2.5M direct capital raise; shares down 3%</a></h4><ul><li>Check-cap (<a href='https://seekingalpha.com/symbol/CHEK' title='Check-Cap Ltd.'>CHEK</a> <font color='red'>-3.4%</font>) inks <a href=\"https://seekingalpha.com/pr/17007210-check-cap-ltd-announces-2_5-million-registered-direct-offering\" target=\"_blank\">agreements</a> with institutional investors to sell 2,272,640 ordinary shares at $1.10 per share. Buyers will also receive unregistered five-year warrants to purchase up to 1,704,480 ordinary shares at $1.25.</li><li>Gross proceeds will be ~$2.5M (~$4.6M if the warrants are exercised in full).</li><li>Net proceeds will fund the continued development of C-Scan and general corporate purposes.</li><li>Friday's close was $1.19.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313528\" data-linked=\"Check-Cap secures $2.5M direct capital raise; shares down 3%\" data-tweet=\"$CHEK - Check-Cap secures $2.5M direct capital raise; shares down 3% https://seekingalpha.com/news/3313528-check-cap-secures-2_5m-direct-capital-raise-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3313528-check-cap-secures-2_5m-direct-capital-raise-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313522\" data-ts=\"1511191634\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACST\" target=\"_blank\">ACST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313522-acasti-pharma-advancing-potential-deal-to-commercialize-capre-in-asia-shares-ahead-75\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acasti Pharma advancing potential deal to commercialize CaPre in Asia; shares ahead 75%</a></h4><ul><li>Thinly traded nano cap Acasti Pharma (<a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma, Inc.'>ACST</a> <font color='green'>+74.8%</font>) is up on a whopping 317x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/17007023-acasti-pharma-announces-development-commercialization-discussions-progressing-leading-china\" target=\"_blank\">announcement </a>that it has entered into a non-binding term sheet with a leading Chinese pharmaceutical company that it expects to lead to a formal license agreement for the commercialization high triglyceride treatment <a href=\"http://www.acastipharma.com/capre/\" target=\"_blank\">CaPre </a>(omega-3 phospholipid) in certain Asian countries including China.</li><li>Under the terms of the formal agreement, if consummated, Acasti will receive $8M upfront, up to $125M in milestones and tiered double-digit royalties on net sales.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3254456-acasti-pharma-proceed-late-stage-development-capre-treatment-high-triglycerides-shares-ahead\" target=\"_blank\">Acasti Pharma to proceed with late-stage development of CaPre for the treatment of high triglycerides; shares ahead 7%</a> (March 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313522\" data-linked=\"Acasti Pharma advancing potential deal to commercialize CaPre in Asia; shares ahead 75%\" data-tweet=\"$ACST - Acasti Pharma advancing potential deal to commercialize CaPre in Asia; shares ahead 75% https://seekingalpha.com/news/3313522-acasti-pharma-advancing-potential-deal-to-commercialize-capre-in-asia-shares-ahead-75?source=tweet\" data-url=\"https://seekingalpha.com/news/3313522-acasti-pharma-advancing-potential-deal-to-commercialize-capre-in-asia-shares-ahead-75\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313520\" data-ts=\"1511190978\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMC\" target=\"_blank\">AMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313520-theater-stocks-in-retreat-after-justice-league-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Theater stocks in retreat after Justice League disappoints</a></h4><ul> <li>Theater stocks are in reverse after box office numbers for <em>Justice League</em> disappointed.</li> <li>The Warner Bros. superhero film failed to reach $100M for its opening weekend and only earned a B+ rating from <a href=\"https://www.cinemascore.com/\" target=\"_blank\">CinemaScore</a>.</li> <li>Decliners include AMC Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a>) <font color='red'>-4.8%</font>, Cinemark Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CNK' title='Cinemark Holdings, Inc'>CNK</a>) <font color='red'>-2.8%</font>, IMAX (NYSE:<a href='https://seekingalpha.com/symbol/IMAX' title='IMAX Corporation'>IMAX</a>) <font color='red'>-2.8%</font>, Regal Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/RGC' title='Regal Entertainment Group'>RGC</a>) <font color='red'>-2.8%</font>, Marcus Corp (NYSE:<a href='https://seekingalpha.com/symbol/MCS' title='Marcus Corporation'>MCS</a>) <font color='red'>-1.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313520\" data-linked=\"Theater stocks in retreat after Justice League disappoints\" data-tweet=\"$AMC $AMC $CNK - Theater stocks in retreat after Justice League disappoints https://seekingalpha.com/news/3313520-theater-stocks-in-retreat-after-justice-league-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3313520-theater-stocks-in-retreat-after-justice-league-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313519\" data-ts=\"1511190439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MKSI\" target=\"_blank\">MKSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313519-index-adds-lift-mks-instruments-invesco-mortgage-tactile-systems\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Index adds lift MKS Instruments, Invesco Mortgage, Tactile Systems</a></h4><ul><li>With Brocade Systems sold to Broadcom, MKS Instruments (<a href='https://seekingalpha.com/symbol/MKSI' title='MKS Instruments, Inc.'>MKSI</a> <font color='green'>+2.4%</font>) will replace it in the S&amp;P MidCap 400, effective Wednesday.</li><li>Replacing MKS in the S&amp;P SmallCap 600 will be Invesco Mortgage (<a href='https://seekingalpha.com/symbol/IVR' title='Invesco Mortgage Capital Inc.'>IVR</a> <font color='green'>+3.8%</font>).</li><li>Tactile Systems (<a href='https://seekingalpha.com/symbol/TCMD' title='Tactile Systems Technology'>TCMD</a> <font color='green'>+11.6%</font>) is replacing Lumos Networks in the S&amp;P SmallCap 600 as Lumos' sale to EQT Infrastructure closed today.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17006653-mks-instruments-set-join-s-and-p-midcap-400-invesco-mortgage-capital-tactile-systems\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3313519\" data-linked=\"Index adds lift MKS Instruments, Invesco Mortgage, Tactile Systems\" data-tweet=\"$MKSI $MKSI $IVR - Index adds lift MKS Instruments, Invesco Mortgage, Tactile Systems https://seekingalpha.com/news/3313519-index-adds-lift-mks-instruments-invesco-mortgage-tactile-systems?source=tweet\" data-url=\"https://seekingalpha.com/news/3313519-index-adds-lift-mks-instruments-invesco-mortgage-tactile-systems\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313518\" data-ts=\"1511190410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLPH\" target=\"_blank\">DLPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313518-delphi-automotive-rallies-on-m-buzz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Delphi Automotive rallies on M&amp;A buzz</a></h4><ul> <li>Shares of Delphi Automotive (<a href='https://seekingalpha.com/symbol/DLPH' title='Delphi Technologies PLC'>DLPH</a> <font color='green'>+3%</font>) are active in morning trading on some M&amp;A speculation.</li> <li>Bank of America Merrill Lynch kickstarted the action by suggesting that the early timeline for the company's spin-off could indicate one of the new entities is a target of interested buyers looking to boost their autonomous, shared mobility or electric car businesses.</li> <li>BAML upgrades Delphi to Buy from Neutral and assigns a price target of $120.</li><li>Sources: Bloomberg, CNBC</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313518\" data-linked=\"Delphi Automotive rallies on M&amp;A buzz\" data-tweet=\"$DLPH - Delphi Automotive rallies on M&amp;A buzz https://seekingalpha.com/news/3313518-delphi-automotive-rallies-on-m-buzz?source=tweet\" data-url=\"https://seekingalpha.com/news/3313518-delphi-automotive-rallies-on-m-buzz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313510\" data-ts=\"1511189467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLXN\" target=\"_blank\">FLXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313510-flexion-launches-zilretta-in-u-s-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flexion launches Zilretta in U.S.; shares ahead 2%</a></h4><ul><li>Flexion Therapeutics (<a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a> <font color='green'>+1.9%</font>) <a href=\"https://seekingalpha.com/pr/17006922-flexion-therapeutics-announces-full-commercial-launch-nationwide-availability-zilretta\" target=\"_blank\">commences</a> the full U.S. commercial launch of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for the treatment of knee pain due to osteoarthritis. The FDA approved it last month and it has been available on a limited basis since October 23.</li><li>The company says it has hired over 100 sales reps to promote the product.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313510\" data-linked=\"Flexion launches Zilretta in U.S.; shares ahead 2%\" data-tweet=\"$FLXN - Flexion launches Zilretta in U.S.; shares ahead 2% https://seekingalpha.com/news/3313510-flexion-launches-zilretta-in-u-s-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3313510-flexion-launches-zilretta-in-u-s-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313505\" data-ts=\"1511188845\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNST\" target=\"_blank\">MNST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313505-susquehanna-negative-on-monster-beverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna negative on Monster Beverage</a></h4><ul> <li>Monster Beverage (<a href='https://seekingalpha.com/symbol/MNST' title='Monster Beverage Corp.'>MNST</a> <font color='red'>-0.9%</font>) trades lower after taking on a downgrade from Susquehanna.</li> <li>Analyst Pablo Zuanic warns about \"misplaced\" enthusiasm over a Coca-Cola bid for the beverage company.</li> <li>\"We think the run-up is explained by expectations KO would announce or hint at a purchase of MNST at last week&rsquo;s seminar. But with FCF at KO pretty much all going to dividends, and the company stating share buybacks would only be done to cover stock option dilution, we are hard pressed to see KO forking our $34Bn (taking a 20% premium) to buy the 82% of shares it does not own,\" reasons Zuanic.</li> <li>Susquehanna drops Monster to Negative from Neutral and sets a price target of $51 (17% downside).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313505\" data-linked=\"Susquehanna negative on Monster Beverage\" data-tweet=\"$MNST - Susquehanna negative on Monster Beverage https://seekingalpha.com/news/3313505-susquehanna-negative-on-monster-beverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3313505-susquehanna-negative-on-monster-beverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313504\" data-ts=\"1511188605\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCEHY\" target=\"_blank\">TCEHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313504-tencent-crosses-500b-market-cap\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tencent crosses $500B market cap</a></h4><ul><li>        Tencent (<a href='https://seekingalpha.com/symbol/TCEHY' title='Tencent Holding Ltd. ADR'>OTCPK:TCEHY</a>, <a href='https://seekingalpha.com/symbol/TCTZF' title='Tencent Holding Ltd.'>OTCPK:TCTZF</a>) pushed over a $500B valuation today as shares&nbsp;<font color='green'>rose over 4%</font>&nbsp;following last week&rsquo;s stellar earnings report.</li><li>                  Tencent becomes the first Chinese tech company to cross that mark.    </li><li>               Alibaba&rsquo;s market cap is $60.7B, and Baidu stands at $10.6B. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3312573-tencent-reports-stellar-q3-plans-increased-focus-digital-content\" target=\"_blank\">Tencent reports stellar Q3, plans increased focus on digital content</a> (Nov. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313504\" data-linked=\"Tencent crosses $500B market cap\" data-tweet=\"$TCEHY $TCEHY $TCTZF - Tencent crosses $500B market cap https://seekingalpha.com/news/3313504-tencent-crosses-500b-market-cap?source=tweet\" data-url=\"https://seekingalpha.com/news/3313504-tencent-crosses-500b-market-cap\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313499\" data-ts=\"1511188028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BITA\" target=\"_blank\">BITA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313499-bitautominus-7_3-yixin-options-drive-wider-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitauto -7.3% as Yixin options drive wider loss</a></h4><ul>   <li>Bitauto Holdings (NYSE:<a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a>) is <font color='red'>7.3% lower</font> premarket after missing expectations with a headline loss that widened due to newly granted options in its <a href=\"https://seekingalpha.com/news/3313393-bitauto-beats-0_03-beats-revenue\" target=\"_blank\">Q3 earnings report</a>.</li>    <li>Net loss grew to 510.2M yuan (about $76.2M) from a loss of 47.4M yuan ($7.1M) a year ago, mainly due to newly grated options by Yixin to its employees in Q3. Non-GAAP net income rose 78.5%, though, to 231.8M yuan (about $34.8M).</li>    <li>Non-GAAP diluted EPS was $0.23.</li>    <li>Revenue by business: Advertising and subscriptions, 1.07B yuan ($161.1M), up 19.3%: Transaction services, 1.05B yuan ($158.4M), up 145.7%; Digital marketing solutions, 218.9M yuan ($32.9M), up 10.6%.</li>    <li>Cash and equivalents came to 6.49B yuan ($975M). Employees were up 33.8% Y/Y to 8,379.</li>    <li>For Q4 it's expecting revenues of 2.4B-2.45B yuan ($360.7M-$368.2M, a 37.2%-40.1% increase Y/Y and in line with expectations for $362.33M). Excluding direct vehicle sales, the forecast is a 51.2%-54.3% net revenue gain Y/Y.</li>    <li><a href=\"https://seekingalpha.com/pr/17006802-bitauto-announces-third-quarter-2017-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3313499\" data-linked=\"Bitauto -7.3% as Yixin options drive wider loss\" data-tweet=\"$BITA - Bitauto -7.3% as Yixin options drive wider loss https://seekingalpha.com/news/3313499-bitautominus-7_3-yixin-options-drive-wider-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3313499-bitautominus-7_3-yixin-options-drive-wider-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313498\" data-ts=\"1511187972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CZZ\" target=\"_blank\">CZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313498-cosanplus-9-on-tender-offer-to-buy-back-up-to-200m-in-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cosan +9% on tender offer to buy back up to $200M in shares</a></h4><ul>     <li>Cosan (NYSE:<a href='https://seekingalpha.com/symbol/CZZ' title='Cosan Limited'>CZZ</a>)&nbsp;<font color='green'>+8.7%</font>&nbsp;premarket after announcing a tender offer to <a href=\"https://seekingalpha.com/pr/17006907-cosan-limited-announces-commencement-tender-offer-repurchase-u-s-200000-000_00-class-common\" target=\"_blank\">buy back</a> up to $200M of its common shares at prices in the $9.23-$9.65 range; CZZ's NYSE closing price last Friday was $8.39.</li>     <li>If the tender offer is fully subscribed, CZZ would repurchase 12.3%-12.8% of its issued and outstanding shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313498\" data-linked=\"Cosan +9% on tender offer to buy back up to $200M in shares\" data-tweet=\"$CZZ - Cosan +9% on tender offer to buy back up to $200M in shares https://seekingalpha.com/news/3313498-cosanplus-9-on-tender-offer-to-buy-back-up-to-200m-in-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3313498-cosanplus-9-on-tender-offer-to-buy-back-up-to-200m-in-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313496\" data-ts=\"1511187879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313496-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+37%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3313133-diana-containerships-reports-q3-results\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='green'>+28%</font>&nbsp;on Axon patent <a href=\"https://seekingalpha.com/news/3313459-digital-ally-plus-15-percent-axon-patent-ruling\" target=\"_blank\">ruling</a>.</li>     <li><a href='https://seekingalpha.com/symbol/ARAY' title='Accuray Incorporated'>ARAY</a> <font color='green'>+10%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CZZ' title='Cosan Limited'>CZZ</a> <font color='green'>+10%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17006907-cosan-limited-announces-commencement-tender-offer-repurchase-u-s-200000-000_00-class-common\" target=\"_blank\">repurchase</a> of shares.</li>     <li><a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='green'>+10%</font>&nbsp;on $12.5M Army <a href=\"https://seekingalpha.com/news/3313474-xg-technology-announces-12_5m-army-contract\" target=\"_blank\">contract</a>.</li>     <li><a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='green'>+9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3313434-egalet-receives-grant-innobooster-develop-novel-application-guardian-technology\" target=\"_blank\">receiving</a> a grant from InnoBooster to develop a novel application of Guardian Technology.</li>     <li>CAVM <font color='green'>+9%</font>&nbsp;as Marvell confirms $6B <a href=\"https://seekingalpha.com/news/3313424-marvell-confirms-6b-deal-cavium\" target=\"_blank\">deal</a>.</li>     <li><a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a> <font color='green'>+8%</font>&nbsp;as <a href=\"https://seekingalpha.com/news/3313429-ziopharms-gene-therapy-candidate-ad-rts-hilminus-12-shows-positive-effect-treatment-resistant\" target=\"_blank\">gene therapy</a> candidate Ad-RTS-hIL-12 shows positive effect in treatment-resistant brain cancer in early-stage study.</li>     <li><a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3313479-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='green'>+7%.</font></li>     <li><a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='green'>+7%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/pr/17007028-celsion-announces-publication-study-thermodox-ultrasound-tardox-study-protocol-journal\" target=\"_blank\">publication</a>&nbsp;of the manuscript, \"Clinical trial protocol for TARDOX.</li>     <li><a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3313438-piper-jaffray-upgrades-3d-systems\" target=\"_blank\">positive</a> upgrade by PiperJaffray.</li>     <li><a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/DBVT' title='DBV Technologies'>DBVT</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+6%</font></li>     <li><a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3313478-intra-cellular-therapies-receives-fda-fast-track-designation-lumateperone-treatment\" target=\"_blank\">receiving</a> FDA Fast Track designation for Lumateperone for the treatment of Schizophrenia.</li>     <li><a href='https://seekingalpha.com/symbol/TOUR' title='Tuniu Corporation'>TOUR</a> <font color='green'>+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313496\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$DCIX $DGLY $ARAY - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3313496-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3313496-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313493\" data-ts=\"1511187639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVE\" target=\"_blank\">FIVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313493-loop-capital-cautious-on-five-below\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loop Capital cautious on Five Below</a></h4><ul> <li>Loop Capital downgrades Five Below (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below'>FIVE</a>) after watching shares jump about 4% last week to stretch out valuation.</li> <li>The firm assigns a Hold rating and price target of $60 on the retailer. Five Below peaked at a 52-week high of $60.12 on Friday.</li> <li>Five Below is due to spill <a href=\"http://investor.fivebelow.com/news-releases/news-release-details/five-below-inc-announces-third-quarter-fiscal-2017-earnings\" target=\"_blank\">quarterly earnings</a> on November 30.</li> <li>FIVE <font color='red'>-1.34%</font> premarket to $59.10 on light volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313493\" data-linked=\"Loop Capital cautious on Five Below\" data-tweet=\"$FIVE - Loop Capital cautious on Five Below https://seekingalpha.com/news/3313493-loop-capital-cautious-on-five-below?source=tweet\" data-url=\"https://seekingalpha.com/news/3313493-loop-capital-cautious-on-five-below\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313491\" data-ts=\"1511187510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDT\" target=\"_blank\">MDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313491-fda-oks-medtronics-next-gen-azure-pacers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Medtronic&#39;s next gen Azure pacers</a></h4><ul><li>The FDA <a href=\"http://newsroom.medtronic.com/phoenix.zhtml?c=251324&amp;p=irol-newsArticle&amp;ID=2317897\" target=\"_blank\">approves </a>Medtronic plc's (NYSE:<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a>) Azure pacemakers with BlueSync technology in single and dual chamber models. The Azure XT MRI and Azure S MRI are designed to last 27% longer than the previous version. Both are MRI- compatible in 1.5 or 3 Tesla machines.</li><li>Market launch is underway.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket but only on 92 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313491\" data-linked=\"FDA OKs Medtronic&#39;s next gen Azure pacers\" data-tweet=\"$MDT - FDA OKs Medtronic&#39;s next gen Azure pacers https://seekingalpha.com/news/3313491-fda-oks-medtronics-next-gen-azure-pacers?source=tweet\" data-url=\"https://seekingalpha.com/news/3313491-fda-oks-medtronics-next-gen-azure-pacers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313487\" data-ts=\"1511187041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTD\" target=\"_blank\">TTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313487-trade-desk-announces-new-cmo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trade Desk announces new CMO</a></h4><ul><li>        The Trade Desk (NASDAQ:<a href='https://seekingalpha.com/symbol/TTD' title='The Trade Desk'>TTD</a>) <a href=\"https://seekingalpha.com/pr/17007269-trade-desk-appoints-susan-vobejda-chief-marketing-officer\" target=\"_blank\">appoints</a> Susan Vobejda as Chief Marketing Officer.</li><li>               Vobejda previously served as the EVP and CMO of fashion brand Tory Burch and was a founding exec and GM of Bloomberg&rsquo;s Media Distribution division.&nbsp;</li><li>               Trade Desk shares are&nbsp;<font color='green'>up 1.14%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3313487\" data-linked=\"Trade Desk announces new CMO\" data-tweet=\"$TTD - Trade Desk announces new CMO https://seekingalpha.com/news/3313487-trade-desk-announces-new-cmo?source=tweet\" data-url=\"https://seekingalpha.com/news/3313487-trade-desk-announces-new-cmo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313486\" data-ts=\"1511187027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313486-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='red'>-14%</font>.</li><li><a href='https://seekingalpha.com/symbol/MRDN' title='Meridian Waste Solutions, Inc.'>OTCQB:MRDN</a> <font color='red'>-9%</font>.</li><li><a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/MICT' title='Micronet Enertec Technologies, Inc.'>MICT</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3313413-micronet-enertec-reports-q3-results\" target=\"_blank\">Q3 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3313393-bitauto-beats-0_03-beats-revenue\" target=\"_blank\">Q3 earnings</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3313486\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$CHFS $MRDN $ANTH - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3313486-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3313486-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313479\" data-ts=\"1511186790\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEMD\" target=\"_blank\">AEMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313479-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Aethlon Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>) initiated with Buy rating and $3 (209% upside) price target by H.C. Wainwright.</li><li>Aimmune Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics'>AIMT</a>) initiated with Buy rating and $60 (71% upside) price target by Roth Capital.</li><li>Ablynx (NASDAQ:<a href='https://seekingalpha.com/symbol/ABLX' title='Ablynx NV'>ABLX</a>) initiated with Buy rating by Ladenburg Thalmann. Initiated with Outperform rating and $33 (57% upside) by Robert W. Baird.</li><li>Innoviva (NASDAQ:<a href='https://seekingalpha.com/symbol/INVA' title='Innoviva, Inc.'>INVA</a>) initiated with Hold rating by Deutsche Bank.</li><li>Catabasis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a>) upgraded to Buy with a $2.50 (54% upside) price target by Citigroup.</li><li>Kindred Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/KND' title='Kindred Healthcare, Inc.'>KND</a>) upgraded to Hold with a $7 (flat) price target by Stifel.</li><li>Advanced Accelerator (NASDAQ:<a href='https://seekingalpha.com/symbol/AAAP' title='Advanced Accelerator Applications'>AAAP</a>) downgraded to Neutral by JPMorgan after Novartis bid.</li><li>Almost Family (NASDAQ:<a href='https://seekingalpha.com/symbol/AFAM' title='Almost Family Inc'>AFAM</a>) downgraded to Sector Perform with a $62 (flat) price target by RBC.</li><li>Cardinal Health (NYSE:<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a>) downgraded to Underweight with a $51 (11% downside risk) price target by Morgan Stanley on potential encroachment by Amazon. Shares are down&nbsp;<font color='red'>3%</font>&nbsp;premarket.</li><li>Ligand Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a>) downgraded to Sell with a $105 (25% downside risk) price target by Deutsche Bank.</li><li>Prothena (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTA' title='Prothena Corp plc'>PRTA</a>) downgraded to Neutral by Wedbush.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3313479\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$AEMD $AEMD $AIMT - Premarket analyst action - healthcare https://seekingalpha.com/news/3313479-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3313479-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313478\" data-ts=\"1511186337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITCI\" target=\"_blank\">ITCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313478-intra-cellular-therapies-receives-fda-fast-track-designation-for-lumateperone-for-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intra-Cellular Therapies receives FDA Fast Track designation for Lumateperone for the treatment of Schizophrenia</a></h4><ul> <li>FDA has <a href=\"https://seekingalpha.com/pr/17006894-intra-cellular-therapies-receives-fda-fast-track-designation-lumateperone-treatment\" target=\"_blank\">granted</a>&nbsp;Fast Track designation to&nbsp;Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a>) for lumateperone for the treatment of schizophrenia.</li><li>The FDA&rsquo;s Fast Track designation is designed to facilitate the development and expedite the review of drug candidates to treat serious and life-threatening conditions. Fast Track designation may allow for more frequent meetings and communications to discuss a drug's development plans and review process.</li>      <li>Lumateperone, is a molecule that provides selective and simultaneous modulation of serotonin, dopamine, and glutamate&mdash;three neurotransmitter pathways implicated in severe mental illness.</li><li>Shares are up&nbsp;<font color='green'>5%</font>&nbsp;premarket on modest volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3313478\" data-linked=\"Intra-Cellular Therapies receives FDA Fast Track designation for Lumateperone for the treatment of Schizophrenia\" data-tweet=\"$ITCI - Intra-Cellular Therapies receives FDA Fast Track designation for Lumateperone for the treatment of Schizophrenia https://seekingalpha.com/news/3313478-intra-cellular-therapies-receives-fda-fast-track-designation-for-lumateperone-for-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3313478-intra-cellular-therapies-receives-fda-fast-track-designation-for-lumateperone-for-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313474\" data-ts=\"1511185674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XGTI\" target=\"_blank\">XGTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313474-xg-technology-announces-12_5m-army-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XG Technology announces $12.5M Army contract</a></h4><ul><li>        Wireless video solution provider xG Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a>) <a href=\"https://seekingalpha.com/pr/17006877-xg-technologys-imt-vislink-business-awarded-12_5-million-us-army-contract-hand-held\" target=\"_blank\">announces</a> a $12.5M contract with the U.S. Army.</li><li>               The company will supply hand-held intelligence and surveillance receiver devices.&nbsp;</li><li>               Contract ends on September 24, 2020.&nbsp;</li><li>               XG shares are&nbsp;<font color='green'>up 9%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3313474\" data-linked=\"XG Technology announces $12.5M Army contract\" data-tweet=\"$XGTI $XGTI-OLD - XG Technology announces $12.5M Army contract https://seekingalpha.com/news/3313474-xg-technology-announces-12_5m-army-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3313474-xg-technology-announces-12_5m-army-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313473\" data-ts=\"1511185636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313473-merck-under-pressure-premarket-on-positive-data-tecentriq-data-in-lung-cancer-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merck under pressure premarket on positive data Tecentriq data in lung cancer, shares down 2% premarket</a></h4><ul><li>Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) is down&nbsp;<font color='red'>2%</font>&nbsp;premarket on increased volume in apparent reaction to Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) <a href=\"https://www.roche.com/media/store/releases/med-cor-2017-11-20.htm\" target=\"_blank\">announcement </a>of positive Phase 3 data on the combination of TECENTRIQ (atezolizumab), Avastin (bevacizumab) and chemo (paclitaxel and carboplatin) in patients with advanced nonsquamous non-small cell lung cancer &#40;NSCLC&#41;.</li><li>In a first-line setting, treatment with TECENTRIQ produced a statistically significant and clinically meaningful reduction in progression-free survival &#40;PFS&#41; compared to Avastin plus chemo. Overall survival data should be available in H1 2018.</li><li>The results will be presented next month at ESMO in Geneva.</li><li>Merck's KEYTRUDA (pembrolizumab) is also approved to treat nonsquamous NSCLC in a first-line setting.</li><li>Roche is up&nbsp;<font color='green'>7%</font>&nbsp;in Switzerland.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313473\" data-linked=\"Merck under pressure premarket on positive data Tecentriq data in lung cancer, shares down 2% premarket\" data-tweet=\"$MRK $MRK $RHHBY - Merck under pressure premarket on positive data Tecentriq data in lung cancer, shares down 2% premarket https://seekingalpha.com/news/3313473-merck-under-pressure-premarket-on-positive-data-tecentriq-data-in-lung-cancer-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3313473-merck-under-pressure-premarket-on-positive-data-tecentriq-data-in-lung-cancer-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313471\" data-ts=\"1511185454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMY\" target=\"_blank\">HMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313471-output-harmony-golds-reportedly-masimong-mine-halted-after-fatality\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Output at Harmony Gold&#39;s reportedly Masimong mine halted after fatality</a></h4><ul><li>Harmony Gold (NYSE:<a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a>) <font color='red'>-2.7%</font> premarket on news that one of its miners had <a href=\"https://www.news24.com/SouthAfrica/News/miner-dies-at-harmony-gold-mine-20171120\" target=\"_blank\">died</a> over the weekend in a \"fall of ground incident\" at its Masimong mine in South Africa.</li><li>The incident, which the company says it is still investigating, reportedly has stopped production at the mine.</li><li>Masimong's production has been declining steadily in recent years and was <a href=\"https://www.harmony.co.za/our-business/our-operations/masimong\" target=\"_blank\">negatively impacted</a> by safety stoppages during 2016.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313471\" data-linked=\"Output at Harmony Gold&#39;s reportedly Masimong mine halted after fatality\" data-tweet=\"$HMY - Output at Harmony Gold&#39;s reportedly Masimong mine halted after fatality https://seekingalpha.com/news/3313471-output-harmony-golds-reportedly-masimong-mine-halted-after-fatality?source=tweet\" data-url=\"https://seekingalpha.com/news/3313471-output-harmony-golds-reportedly-masimong-mine-halted-after-fatality\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313469\" data-ts=\"1511185069\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313469-gbh-insights-raises-amazon-price-target-ahead-of-blowout-holiday-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GBH Insights raises Amazon price target ahead of &quot;blowout&quot; holiday quarter</a></h4><ul><li>        GBH Insights analyst Daniel Ives <a href=\"https://www.cnbc.com/2017/11/20/amazon-set-for-blowout-holidays-shares-to-rise-12-percent-analyst-says.html\" target=\"_blank\">says</a> Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) will have a &ldquo;blowout&rdquo; holiday quarter with Prime members spending 20% to 25% more this season.</li><li>               Ives cites the higher number of Prime members this year and the Whole Foods acquisition as driving Amazon to beat top-line revenue estimates by 3% to 5%. Consensus estimates have revenue at $59.7B for the quarter.&nbsp;</li><li>               Ives raises Amazon&rsquo;s price target from $1,185 to $1,270.&nbsp;</li><li>                  Amazon&rsquo;s holiday quarter last year achieved high profits but missed revenue estimates.    </li><li>               Amazon shares are&nbsp;<font color='green'>up 0.19%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313119-amazon-going-truck-drivers\" target=\"_blank\">Amazon is going after truck drivers</a> (Nov. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313469\" data-linked=\"GBH Insights raises Amazon price target ahead of &quot;blowout&quot; holiday quarter\" data-tweet=\"$AMZN - GBH Insights raises Amazon price target ahead of &quot;blowout&quot; holiday quarter https://seekingalpha.com/news/3313469-gbh-insights-raises-amazon-price-target-ahead-of-blowout-holiday-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3313469-gbh-insights-raises-amazon-price-target-ahead-of-blowout-holiday-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313465\" data-ts=\"1511184951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313465-fda-grants-alnylam-btd-for-patisiran-for-treatment-of-hereditary-attr-amyloidosis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA grants Alnylam BTD for Patisiran for the treatment of hereditary ATTR Amyloidosis with Polyneuropathy</a></h4><ul> <li>Alnylam       Pharmaceuticals&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) <a href=\"https://seekingalpha.com/pr/17006870-u-s-food-drug-administration-fda-grants-alnylam-breakthrough-therapy-designation-btd\" target=\"_blank\">announces</a> that the FDA has       granted Breakthrough Therapy Designation &#40;BTD&#41; for <a href=\"https://de.wikipedia.org/wiki/Patisiran\" target=\"_blank\">patisiran</a>, an       investigational RNAi therapeutic targeting transthyretin for the       treatment of adults with hereditary <a href=\"https://en.wikipedia.org/wiki/Transthyretin-related_hereditary_amyloidosis\" target=\"_blank\">transthyretin-mediated ATTR       amyloidosis</a> with polyneuropathy.</li>     <li>BTD is intended to       expedite the development and review of drugs for the treatment of       serious or life-threatening conditions based on clinical evidence.</li>     <li>Alnylam has initiated a rolling New Drug Application for patisiran       and expects the last submission by the end of 2017.</li><li>The BTD is based on positive APOLLO Phase 3 study.</li>     <li>Alnylam will commercialize patisiran in       the U.S., Canada and Western Europe, with Sanofi Genzyme commercializing       the product in the rest of the world.</li><li>Shares are down&nbsp;<font color='red'>1%</font>&nbsp;premarket on light volume.</li>               </ul><div class=\"tiny-share-widget\" data-id=\"3313465\" data-linked=\"FDA grants Alnylam BTD for Patisiran for the treatment of hereditary ATTR Amyloidosis with Polyneuropathy\" data-tweet=\"$ALNY - FDA grants Alnylam BTD for Patisiran for the treatment of hereditary ATTR Amyloidosis with Polyneuropathy https://seekingalpha.com/news/3313465-fda-grants-alnylam-btd-for-patisiran-for-treatment-of-hereditary-attr-amyloidosis?source=tweet\" data-url=\"https://seekingalpha.com/news/3313465-fda-grants-alnylam-btd-for-patisiran-for-treatment-of-hereditary-attr-amyloidosis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313463\" data-ts=\"1511184493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313463-shire-and-bioverativ-under-pressure-premarket-on-roches-positive-hemlibra-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire and Bioverativ under pressure premarket on Roche&#39;s positive Hemlibra data</a></h4><ul><li>Roche's announcement of positive Phase 3 data on hemophilia med Hemlibra (emicizumab) in hemophilia A patients without inhibitors to factor VIII pressures competitors Shire plc (NASDAQ:<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a>) and Bioverativ (NASDAQ:<a href='https://seekingalpha.com/symbol/BIVV' title='Bioverativ Inc.'>BIVV</a>) in premarket trading.</li><li>SHPG is down&nbsp;<font color='red'>4%</font>&nbsp;on average volume and BIVV is down&nbsp;<font color='red'>6%</font>&nbsp;on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313417-roches-hemlibra-successful-late-stage-study-hemophilia-patients-without-inhibitors-factor\" target=\"_blank\">Roche's Hemlibra successful in late-stage study in hemophilia patients without inhibitors to factor VIII</a> (Nov. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313463\" data-linked=\"Shire and Bioverativ under pressure premarket on Roche&#39;s positive Hemlibra data\" data-tweet=\"$SHPG $SHPG $BIVV - Shire and Bioverativ under pressure premarket on Roche&#39;s positive Hemlibra data https://seekingalpha.com/news/3313463-shire-and-bioverativ-under-pressure-premarket-on-roches-positive-hemlibra-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3313463-shire-and-bioverativ-under-pressure-premarket-on-roches-positive-hemlibra-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313460\" data-ts=\"1511184060\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313460-national-beverage-pops-after-susquehanna-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Beverage pops after Susquehanna upgrade</a></h4><ul> <li>Susquehanna upgrades National Beverage Corp. (NASDAQ:<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a>) to Positive from Neutral.</li> <li>\"We are upgrading to Positive given increased conviction on the sales and bottom-line upside of FIZZ (led by Lacroix), and because of the pullback in the stock since our launch,\" writes Pablo Zuanic.</li> <li>The price target on FIZZ from Susquehanna jumps to $150 from $108.</li> <li>Zuanic's math: \"For valuation purposes we take 25% probability of a company sale scenario (Lacroix at 9x, and remainder at 1.5x) and 75% of no sale (in that case we value FIZZ at 35x P/E ex net cash per share).\"</li> <li>FIZZ <font color='green'>+7.60%</font> premarket to $110.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313460\" data-linked=\"National Beverage pops after Susquehanna upgrade\" data-tweet=\"$FIZZ - National Beverage pops after Susquehanna upgrade https://seekingalpha.com/news/3313460-national-beverage-pops-after-susquehanna-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3313460-national-beverage-pops-after-susquehanna-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313459\" data-ts=\"1511183918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DGLY\" target=\"_blank\">DGLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313459-digital-allyplus-15-on-axon-patent-ruling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Ally +15% on Axon patent ruling</a></h4><ul><li>Digital Ally (NASDAQ:<a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a>) <font color='green'>+15%</font> premarket after <a href=\"https://seekingalpha.com/pr/17006917-digital-ally-announces-significant-development-litigation-axon-enterprise-inc\" target=\"_blank\">announcing</a> that the Federal District Court of Kansas has rejected the request of Axon Enterprise (NASDAQ:<a href='https://seekingalpha.com/symbol/AAXN' title='Axon Enterprise, Inc.'>AAXN</a>) to maintain the stay of the patent lawsuit brought by the company against it.</li><li>The parties will now proceed towards trial.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313459\" data-linked=\"Digital Ally +15% on Axon patent ruling\" data-tweet=\"$DGLY $DGLY $AAXN - Digital Ally +15% on Axon patent ruling https://seekingalpha.com/news/3313459-digital-allyplus-15-on-axon-patent-ruling?source=tweet\" data-url=\"https://seekingalpha.com/news/3313459-digital-allyplus-15-on-axon-patent-ruling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313453\" data-ts=\"1511183528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313453-guggenheim-positive-on-gm-ahead-of-investor-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guggenheim positive on GM ahead of investor event</a></h4><ul> <li>Guggenheim issues a positive outlook on General Motors (NYSE:<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a>) on \"increased comfort\" on the outlook the automaker will issue at its investor meeting on November 30.</li> <li>The investor event is focused on GM's vision for an <a href=\"https://www.gm.com/events/5265893.html\" target=\"_blank\">autonomous future</a>.</li> <li>Guggenheim thinks GM will show off its path to monetizing its mobility and autonomous future. The firm ugrades GM to Buy from Neutral and assigns a price target of $52.</li> <li>GM <font color='green'>+0.73%</font> premarket to $44.20 vs. a 52-week trading range of $31.92 to $46.76.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313453\" data-linked=\"Guggenheim positive on GM ahead of investor event\" data-tweet=\"$GM - Guggenheim positive on GM ahead of investor event https://seekingalpha.com/news/3313453-guggenheim-positive-on-gm-ahead-of-investor-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3313453-guggenheim-positive-on-gm-ahead-of-investor-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313450\" data-ts=\"1511183244\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACOR\" target=\"_blank\">ACOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313450-acorda-drops-development-of-tozadenant-on-safety-concerns-shares-down-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acorda drops development of tozadenant on safety concerns; shares down 4% premarket</a></h4><ul><li>Citing a lack of confidence that it could ensure patients safety by weekly white blood cell count screening, Acorda Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a>) <a href=\"https://seekingalpha.com/pr/17006872-acorda-discontinues-tozadenant-development-program\" target=\"_blank\">terminates</a> development of Parkinson's disease candidate tozadenant. The company made its decision after reviewing new information from its Phase 3 program related to agranulocytosis and associated serious adverse events.</li><li>Last week, the company reported five deaths in the Phase 3, including four cases of agranulocytosis (severe drop in white blood cell count).</li><li>Data from the patients who completed the study (CL-05) will be available in Q1 2018 and will be submitted for presentation at future medical conferences.</li><li>Shares are down&nbsp;<font color='red'>4%</font>&nbsp;premarket on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3312365-acorda-therapeutics-stops-enrollment-long-term-studies-tozadenant-five-fatalities-shares-31\" target=\"_blank\">Acorda Therapeutics stops enrollment in long-term studies of tozadenant after five fatalities; shares down 31% premarket</a> (Nov. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313450\" data-linked=\"Acorda drops development of tozadenant on safety concerns; shares down 4% premarket\" data-tweet=\"$ACOR - Acorda drops development of tozadenant on safety concerns; shares down 4% premarket https://seekingalpha.com/news/3313450-acorda-drops-development-of-tozadenant-on-safety-concerns-shares-down-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3313450-acorda-drops-development-of-tozadenant-on-safety-concerns-shares-down-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313446\" data-ts=\"1511183063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MARA\" target=\"_blank\">MARA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313446-marathon-patent-reports-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marathon Patent reports Q3 results</a></h4><ul><li>Marathon Patent (NASDAQ:<a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>): Q3 EPS of -$0.23</li><li>Revenue of $0.16M (+300.0% Y/Y)</li><li>Shares <font color='green'>+7.91%</font> PM.</li><li><a href='https://seekingalpha.com/pr/17007040-marathon-patent-group-announces-third-quarter-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3313446\" data-linked=\"Marathon Patent reports Q3 results\" data-tweet=\"$MARA - Marathon Patent reports Q3 results https://seekingalpha.com/news/3313446-marathon-patent-reports-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3313446-marathon-patent-reports-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313439\" data-ts=\"1511182700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CROX\" target=\"_blank\">CROX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313439-crocs-falls-after-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crocs falls after downgrade</a></h4><ul> <li>Crocs (NASDAQ:<a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a>) slumps in early trading after CL King &amp; Associates downgrades the retailer to a Neutral from Buy after watching shares race to a 52-week high of $10.86 last week.</li> <li>The firm sees current valuation on Crocs as reflective of the growth prospects over the next six to twelve months.</li> <li>CROX<font color='red'> -2.43%</font> premarket to $10.45</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313439\" data-linked=\"Crocs falls after downgrade\" data-tweet=\"$CROX - Crocs falls after downgrade https://seekingalpha.com/news/3313439-crocs-falls-after-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3313439-crocs-falls-after-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313438\" data-ts=\"1511182569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDD\" target=\"_blank\">DDD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313438-piper-jaffray-upgrades-3d-systems\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray upgrades 3D Systems</a></h4><ul><li>        Piper Jaffray upgrades 3D Systems (NYSE:<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a>) to Neutral from Underweight and maintains a $10 price target. &nbsp;</li><li>        Analyst Troy D. Jensen cites new products coming next year that should recover some market share losses and the significant correction in the share price that now has 3D as the cheapest buy in its competitor group.</li><li>               Jensen does expect some struggles ahead but only for the next 3 to 6 months.&nbsp;</li><li>               Source: Bloomberg First Word&nbsp;</li><li>               3D Systems shares are&nbsp;<font color='green'>up 3.24%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3313438\" data-linked=\"Piper Jaffray upgrades 3D Systems\" data-tweet=\"$DDD - Piper Jaffray upgrades 3D Systems https://seekingalpha.com/news/3313438-piper-jaffray-upgrades-3d-systems?source=tweet\" data-url=\"https://seekingalpha.com/news/3313438-piper-jaffray-upgrades-3d-systems\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313435\" data-ts=\"1511182368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSRO\" target=\"_blank\">TSRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313435-tesaros-zejula-okd-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TESARO&#39;s Zejula OK&#39;d in Europe</a></h4><ul><li>As expected, the European Commission <a href=\"https://seekingalpha.com/pr/17006887-tesaro-announces-european-commission-approval-zejula-women-recurrent-ovarian-cancer\" target=\"_blank\">approves </a>TESARO's (NASDAQ:<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a>) ZEJULA (niraparib) for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete response or partial response to platinum-based chemo.</li><li>The company says ZEJULA is the first once-daily oral PARP inhibitor to be approved in Europe that does not require BRCA mutation or other biomarker testing.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket but only on 300 shares.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295687-european-advisory-group-backs-tesaros-zejula\" target=\"_blank\">European advisory group backs TESARO's Zejula</a> (Sept. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313435\" data-linked=\"TESARO&#39;s Zejula OK&#39;d in Europe\" data-tweet=\"$TSRO - TESARO&#39;s Zejula OK&#39;d in Europe https://seekingalpha.com/news/3313435-tesaros-zejula-okd-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3313435-tesaros-zejula-okd-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313434\" data-ts=\"1511182103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGLT\" target=\"_blank\">EGLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313434-egalet-receives-grant-from-innobooster-to-develop-novel-application-of-guardian-technology\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Egalet receives a grant from InnoBooster to develop a novel application of Guardian Technology</a></h4><ul> <li>Egalet Corporation (<a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a>) <a href=\"https://seekingalpha.com/pr/17006833-egalet-received-grant-innobooster-develop-novel-application-guardian-technology\" target=\"_blank\">announces</a> the company was awarded a grant from InnoBooster to develop a novel oral delivery system using a new application of Egalet's Guardian Technology to develop products in therapeutic areas outside of pain.</li>                   <li>The grant provides non-dilutive funds to support the research project and will cover most of the external expenses needed to explore this opportunity into the pre-clinical stage of development.</li> <li>InnoBooster is a fund under the Danish Growth Fund. The fund's objective is to promote growth and renewal for small and medium-sized enterprises in order to achieve a greater socio-economic return.</li><li>Shares are up&nbsp;<font color='green'>11%</font>&nbsp;premarket on robust volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313434\" data-linked=\"Egalet receives a grant from InnoBooster to develop a novel application of Guardian Technology\" data-tweet=\"$EGLT $ZCOR - Egalet receives a grant from InnoBooster to develop a novel application of Guardian Technology https://seekingalpha.com/news/3313434-egalet-receives-grant-from-innobooster-to-develop-novel-application-of-guardian-technology?source=tweet\" data-url=\"https://seekingalpha.com/news/3313434-egalet-receives-grant-from-innobooster-to-develop-novel-application-of-guardian-technology\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313429\" data-ts=\"1511181746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313429-ziopharms-gene-therapy-candidate-ad-rts-hilminus-12-shows-positive-effect-in-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ZIOPHARM&#39;s gene therapy candidate Ad-RTS-hIL-12 shows positive effect in treatment-resistant brain cancer in early-stage study; shares ahead 13% premarket</a></h4><ul><li>ZIOPHARM (NASDAQ:<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>) is up&nbsp;<font color='green'>13%</font>&nbsp;premarket on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17006886-ziopharm-presents-positive-updated-results-ad-rts-hilminus-12-study-brain-cancer-society\" target=\"_blank\">announcement </a>of positive results from a Phase 1 clinical trial assessing Ad-RTS-hIL-12 + veledimex in patients with recurrent glioblastoma (rGBM). The data were presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology in San Francisco.</li><li>Patients treated with Ad-RTS-hIL-12 plus 20 mg of veledimex (n=20) experienced median overall survival &#40;OS&#41; of 12.5 months compared to five-to-eights months historically in these patients.</li><li>Four rGM patients in the treatment group who also received low-dose steroids were all surviving at a median follow-up 11.1 months.</li><li>Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of&nbsp;<a href=\"http://en.wikipedia.org/wiki/Interleukin_12\" target=\"_blank\">interleukin-12</a>&nbsp;(IL-12), an essential protein for stimulating a T cell immune response to cancer.&nbsp;<a href=\"http://investors.dna.com/phoenix.zhtml?c=249599&amp;p=irol-newsArticle_Print&amp;ID=1994675\" target=\"_blank\">Veledimex&nbsp;</a>is an oral activator ligand or \"gene switch\" which is used to control the expression of IL-12, a pro-inflammatory cytokine that produces serious side effects if over-expressed.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313155-ziopharm-update-investors-gene-therapy-candidate-brain-cancer-november-20\" target=\"_blank\">ZIOPHARM to update investors on gene therapy candidate for brain cancer November 20</a> (Nov. 17)</li><li><strong>Update</strong>: Shares are now down&nbsp;<font color='red'>7%</font>&nbsp;as investors appear underwhelmed with the <a href=\"http://files.shareholder.com/downloads/ZIOP/5571657749x0x964694/68560D1F-7653-4752-A650-E35B142FCA30/PostSNO_Conference_Call_Nov20_final.pdf\" target=\"_blank\">data presented</a> during the conference call this morning.</li></ul><div class=\"tiny-share-widget\" data-id=\"3313429\" data-linked=\"ZIOPHARM&#39;s gene therapy candidate Ad-RTS-hIL-12 shows positive effect in treatment-resistant brain cancer in early-stage study; shares ahead 13% premarket\" data-tweet=\"$ZIOP - ZIOPHARM&#39;s gene therapy candidate Ad-RTS-hIL-12 shows positive effect in treatment-resistant brain cancer in early-stage study; shares ahead 13% premarket https://seekingalpha.com/news/3313429-ziopharms-gene-therapy-candidate-ad-rts-hilminus-12-shows-positive-effect-in-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3313429-ziopharms-gene-therapy-candidate-ad-rts-hilminus-12-shows-positive-effect-in-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313431\" data-ts=\"1511181447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VWAGY\" target=\"_blank\">VWAGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313431-volkswagen-issues-strong-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Volkswagen issues strong outlook</a></h4><ul> <li>Volkswagen (VLKAY) <a href=\"https://www.reuters.com/article/us-volkswagen-outlook/vw-raises-2020-sales-outlook-on-emerging-market-growth-suvs-idUSKBN1DK197\" target=\"_blank\">boosts</a> its sales outlook after factoring in strong demand for SUVs in emerging markets.</li> <li>The automaker now expects revenue to to increase by at least 25% by 2020 over last year's $255.69B mark.</li> <li>Operating profit guidance from Volkswagen remains the same at 25% growth by 2020.</li> <li>\"Cost discipline, productivity improvements and execution of one-time product launches are certainly vital to reach our goals,\" says Volkswagen CFO Frank Witter.</li> <li>Shares of Volkswagen are <font color='green'>up 1.81%</font> in Frankfurt trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3313431\" data-linked=\"Volkswagen issues strong outlook\" data-tweet=\"$VWAGY - Volkswagen issues strong outlook https://seekingalpha.com/news/3313431-volkswagen-issues-strong-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3313431-volkswagen-issues-strong-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313424\" data-ts=\"1511180903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRVL\" target=\"_blank\">MRVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313424-marvell-confirms-6b-deal-for-cavium\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marvell confirms $6B deal for Cavium</a></h4><ul><li>The cash and stock deal values Cavium (CAVM) at $80 per share. Consideration for each Cavium share will be $40 in cash and 2.1757 Marvell (NASDAQ:<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group, Ltd.'>MRVL</a>) shares.</li><li>The deal is seen generating at least $150M-$175M of annual synergies within 18 months after the close, and is expected to be significantly accretive to revenue growth, margins, and non-GAAP EPS. The sale is expected to close in the middle of 2018.</li><li>Marvell CEO Matt Murphy will run the merged company, and Cavium CEO Syed Ali will continue as strategic advisor and member of the board.</li><li>Alongside, Marvell expects Q3 revenue to be $610M-$620M, and EPS of $0.32-$0.34, ahead of the most recent guidance.</li><li>A conference call is set for 8 ET.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17006875-marvell-cavium-combine-creating-infrastructure-solutions-powerhouse\" target=\"_blank\">Press Release</a></li><li>MRVL&nbsp;<font color='green'>+1.3%</font>, CAVM&nbsp;<font color='green'>+7.5%</font>&nbsp;to $81.50 premarket</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313379-wsj-marvell-technology-set-buy-cavium-6b-deal\" target=\"_blank\">WSJ: Marvell Technology set to buy Cavium in ~$6B deal</a> (Nov. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3313424\" data-linked=\"Marvell confirms $6B deal for Cavium\" data-tweet=\"$MRVL - Marvell confirms $6B deal for Cavium https://seekingalpha.com/news/3313424-marvell-confirms-6b-deal-for-cavium?source=tweet\" data-url=\"https://seekingalpha.com/news/3313424-marvell-confirms-6b-deal-for-cavium\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3313413\" data-ts=\"1511179657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MICT\" target=\"_blank\">MICT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3313413-micronet-enertec-reports-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micronet Enertec reports Q3 results</a></h4><ul><li>Micronet Enertec (NASDAQ:<a href='https://seekingalpha.com/symbol/MICT' title='Micronet Enertec Technologies, Inc.'>MICT</a>): Q3 EPS of -$0.16</li><li>Revenue of $6.93M (+29.5% Y/Y)</li><li>Shares <font color='green'>+1.63%</font> PM.</li><li><a href='https://seekingalpha.com/pr/17006874-micronet-enertec-reports-third-quarter-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3313413\" data-linked=\"Micronet Enertec reports Q3 results\" data-tweet=\"$MICT - Micronet Enertec reports Q3 results https://seekingalpha.com/news/3313413-micronet-enertec-reports-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3313413-micronet-enertec-reports-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:07 AM </div></div></li>","count":73,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}